US20030055491A1 - Anti-arrhythmia devices and methods of use - Google Patents
Anti-arrhythmia devices and methods of use Download PDFInfo
- Publication number
- US20030055491A1 US20030055491A1 US10/192,402 US19240202A US2003055491A1 US 20030055491 A1 US20030055491 A1 US 20030055491A1 US 19240202 A US19240202 A US 19240202A US 2003055491 A1 US2003055491 A1 US 2003055491A1
- Authority
- US
- United States
- Prior art keywords
- tissue
- set forth
- target site
- delivering
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 100
- 230000003288 anthiarrhythmic effect Effects 0.000 title 1
- 206010016654 Fibrosis Diseases 0.000 claims abstract description 50
- 230000004761 fibrosis Effects 0.000 claims abstract description 49
- 206010003119 arrhythmia Diseases 0.000 claims abstract description 43
- 230000001939 inductive effect Effects 0.000 claims abstract description 25
- 206010002329 Aneurysm Diseases 0.000 claims abstract description 19
- 206010061218 Inflammation Diseases 0.000 claims abstract description 15
- 230000004054 inflammatory process Effects 0.000 claims abstract description 15
- 210000002216 heart Anatomy 0.000 claims description 41
- 239000000463 material Substances 0.000 claims description 40
- 230000004044 response Effects 0.000 claims description 35
- 210000003492 pulmonary vein Anatomy 0.000 claims description 27
- 239000000126 substance Substances 0.000 claims description 24
- 210000000056 organ Anatomy 0.000 claims description 22
- 230000001746 atrial effect Effects 0.000 claims description 20
- 239000003814 drug Substances 0.000 claims description 13
- 230000003176 fibrotic effect Effects 0.000 claims description 13
- 210000003462 vein Anatomy 0.000 claims description 13
- 229940079593 drug Drugs 0.000 claims description 12
- 230000001225 therapeutic effect Effects 0.000 claims description 12
- 102000008186 Collagen Human genes 0.000 claims description 10
- 108010035532 Collagen Proteins 0.000 claims description 10
- 102000016942 Elastin Human genes 0.000 claims description 10
- 108010014258 Elastin Proteins 0.000 claims description 10
- 229920001436 collagen Polymers 0.000 claims description 10
- 229920002549 elastin Polymers 0.000 claims description 10
- 230000015572 biosynthetic process Effects 0.000 claims description 9
- 230000002308 calcification Effects 0.000 claims description 8
- 210000003748 coronary sinus Anatomy 0.000 claims description 8
- 210000000702 aorta abdominal Anatomy 0.000 claims description 7
- 239000011248 coating agent Substances 0.000 claims description 6
- 238000000576 coating method Methods 0.000 claims description 6
- 230000001965 increasing effect Effects 0.000 claims description 6
- 208000034693 Laceration Diseases 0.000 claims description 5
- 230000000747 cardiac effect Effects 0.000 claims description 5
- 210000001147 pulmonary artery Anatomy 0.000 claims description 5
- 239000000560 biocompatible material Substances 0.000 claims description 4
- 230000004048 modification Effects 0.000 claims description 4
- 238000012986 modification Methods 0.000 claims description 4
- 230000004663 cell proliferation Effects 0.000 claims description 3
- 208000028867 ischemia Diseases 0.000 claims description 3
- 210000005246 left atrium Anatomy 0.000 claims description 3
- 230000008030 elimination Effects 0.000 claims description 2
- 238000003379 elimination reaction Methods 0.000 claims description 2
- 238000003786 synthesis reaction Methods 0.000 claims description 2
- 229940126585 therapeutic drug Drugs 0.000 claims description 2
- 230000002685 pulmonary effect Effects 0.000 claims 6
- 239000012867 bioactive agent Substances 0.000 claims 2
- 230000002612 cardiopulmonary effect Effects 0.000 claims 1
- 230000000149 penetrating effect Effects 0.000 claims 1
- 230000003014 reinforcing effect Effects 0.000 claims 1
- 230000006793 arrhythmia Effects 0.000 abstract description 32
- 230000036772 blood pressure Effects 0.000 abstract description 13
- 206010020772 Hypertension Diseases 0.000 abstract description 7
- 230000001594 aberrant effect Effects 0.000 abstract description 6
- 210000001519 tissue Anatomy 0.000 description 95
- 206010003658 Atrial Fibrillation Diseases 0.000 description 32
- 230000006870 function Effects 0.000 description 21
- 210000002837 heart atrium Anatomy 0.000 description 21
- 210000004369 blood Anatomy 0.000 description 18
- 239000008280 blood Substances 0.000 description 18
- 210000004027 cell Anatomy 0.000 description 16
- 238000002679 ablation Methods 0.000 description 15
- 239000003795 chemical substances by application Substances 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 230000007246 mechanism Effects 0.000 description 10
- 230000033764 rhythmic process Effects 0.000 description 9
- 210000001367 artery Anatomy 0.000 description 8
- 230000008602 contraction Effects 0.000 description 8
- 230000006378 damage Effects 0.000 description 8
- 208000027418 Wounds and injury Diseases 0.000 description 7
- 230000001413 cellular effect Effects 0.000 description 7
- 210000002808 connective tissue Anatomy 0.000 description 7
- 230000012010 growth Effects 0.000 description 7
- 208000014674 injury Diseases 0.000 description 7
- 210000003205 muscle Anatomy 0.000 description 7
- 230000000638 stimulation Effects 0.000 description 7
- 210000000709 aorta Anatomy 0.000 description 6
- 230000002763 arrhythmic effect Effects 0.000 description 6
- 230000006835 compression Effects 0.000 description 6
- 238000007906 compression Methods 0.000 description 6
- 229920000642 polymer Polymers 0.000 description 6
- 210000001992 atrioventricular node Anatomy 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- HLXZNVUGXRDIFK-UHFFFAOYSA-N nickel titanium Chemical compound [Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni] HLXZNVUGXRDIFK-UHFFFAOYSA-N 0.000 description 5
- 229910001000 nickel titanium Inorganic materials 0.000 description 5
- 239000011148 porous material Substances 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- 238000001356 surgical procedure Methods 0.000 description 5
- 230000002861 ventricular Effects 0.000 description 5
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 4
- 208000031737 Tissue Adhesions Diseases 0.000 description 4
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- 210000005242 cardiac chamber Anatomy 0.000 description 4
- 238000013153 catheter ablation Methods 0.000 description 4
- 230000030833 cell death Effects 0.000 description 4
- 239000002561 chemical irritant Substances 0.000 description 4
- 229910052802 copper Inorganic materials 0.000 description 4
- 239000010949 copper Substances 0.000 description 4
- 238000012377 drug delivery Methods 0.000 description 4
- 230000007831 electrophysiology Effects 0.000 description 4
- 238000002001 electrophysiology Methods 0.000 description 4
- 239000000835 fiber Substances 0.000 description 4
- 210000005003 heart tissue Anatomy 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 230000028709 inflammatory response Effects 0.000 description 4
- 230000001788 irregular Effects 0.000 description 4
- 230000003902 lesion Effects 0.000 description 4
- 210000005244 lower chamber Anatomy 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000007634 remodeling Methods 0.000 description 4
- 230000036573 scar formation Effects 0.000 description 4
- 229910052725 zinc Inorganic materials 0.000 description 4
- 239000011701 zinc Substances 0.000 description 4
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 3
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 3
- 206010019280 Heart failures Diseases 0.000 description 3
- 208000031481 Pathologic Constriction Diseases 0.000 description 3
- 208000003734 Supraventricular Tachycardia Diseases 0.000 description 3
- 206010042600 Supraventricular arrhythmias Diseases 0.000 description 3
- 239000004098 Tetracycline Substances 0.000 description 3
- 239000006096 absorbing agent Substances 0.000 description 3
- 238000004873 anchoring Methods 0.000 description 3
- 239000003146 anticoagulant agent Substances 0.000 description 3
- 230000002490 cerebral effect Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 210000002744 extracellular matrix Anatomy 0.000 description 3
- 239000007943 implant Substances 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000013507 mapping Methods 0.000 description 3
- 238000002483 medication Methods 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- -1 polypropylene Polymers 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 229910001220 stainless steel Inorganic materials 0.000 description 3
- 239000010935 stainless steel Substances 0.000 description 3
- 230000036262 stenosis Effects 0.000 description 3
- 208000037804 stenosis Diseases 0.000 description 3
- 229930101283 tetracycline Natural products 0.000 description 3
- 229960002180 tetracycline Drugs 0.000 description 3
- 235000019364 tetracycline Nutrition 0.000 description 3
- 150000003522 tetracyclines Chemical class 0.000 description 3
- 210000001604 vasa vasorum Anatomy 0.000 description 3
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 102100022875 Hypoxia-inducible factor 1-alpha Human genes 0.000 description 2
- 201000008450 Intracranial aneurysm Diseases 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 206010047281 Ventricular arrhythmia Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 210000003484 anatomy Anatomy 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 238000010009 beating Methods 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 208000006218 bradycardia Diseases 0.000 description 2
- 239000000919 ceramic Substances 0.000 description 2
- 239000002975 chemoattractant Substances 0.000 description 2
- 230000035602 clotting Effects 0.000 description 2
- 238000004891 communication Methods 0.000 description 2
- 239000004020 conductor Substances 0.000 description 2
- 210000004351 coronary vessel Anatomy 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000002224 dissection Methods 0.000 description 2
- 210000000620 electrically active cell Anatomy 0.000 description 2
- 230000010102 embolization Effects 0.000 description 2
- 239000004744 fabric Substances 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 238000010304 firing Methods 0.000 description 2
- 239000003292 glue Substances 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 239000004633 polyglycolic acid Substances 0.000 description 2
- 229950008885 polyglycolic acid Drugs 0.000 description 2
- 239000004626 polylactic acid Substances 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 230000001902 propagating effect Effects 0.000 description 2
- 230000000541 pulsatile effect Effects 0.000 description 2
- LOUPRKONTZGTKE-LHHVKLHASA-N quinidine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-LHHVKLHASA-N 0.000 description 2
- 231100000241 scar Toxicity 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 230000008093 supporting effect Effects 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 238000011477 surgical intervention Methods 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- 230000001960 triggered effect Effects 0.000 description 2
- 210000005243 upper chamber Anatomy 0.000 description 2
- 206010047302 ventricular tachycardia Diseases 0.000 description 2
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 208000006017 Cardiac Tamponade Diseases 0.000 description 1
- 108091006146 Channels Proteins 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- DJBNUMBKLMJRSA-UHFFFAOYSA-N Flecainide Chemical compound FC(F)(F)COC1=CC=C(OCC(F)(F)F)C(C(=O)NCC2NCCCC2)=C1 DJBNUMBKLMJRSA-UHFFFAOYSA-N 0.000 description 1
- 206010018852 Haematoma Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 101001046870 Homo sapiens Hypoxia-inducible factor 1-alpha Proteins 0.000 description 1
- 108050009527 Hypoxia-inducible factor-1 alpha Proteins 0.000 description 1
- ALOBUEHUHMBRLE-UHFFFAOYSA-N Ibutilide Chemical compound CCCCCCCN(CC)CCCC(O)C1=CC=C(NS(C)(=O)=O)C=C1 ALOBUEHUHMBRLE-UHFFFAOYSA-N 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 208000034827 Neointima Diseases 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 208000005228 Pericardial Effusion Diseases 0.000 description 1
- 102000015795 Platelet Membrane Glycoproteins Human genes 0.000 description 1
- 108010010336 Platelet Membrane Glycoproteins Proteins 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 208000035965 Postoperative Complications Diseases 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000002847 Surgical Wound Diseases 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 206010057469 Vascular stenosis Diseases 0.000 description 1
- 208000033774 Ventricular Remodeling Diseases 0.000 description 1
- 208000002223 abdominal aortic aneurysm Diseases 0.000 description 1
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 1
- 150000001241 acetals Chemical class 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 229960005260 amiodarone Drugs 0.000 description 1
- IYIKLHRQXLHMJQ-UHFFFAOYSA-N amiodarone Chemical compound CCCCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(I)=C(OCCN(CC)CC)C(I)=C1 IYIKLHRQXLHMJQ-UHFFFAOYSA-N 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 208000007474 aortic aneurysm Diseases 0.000 description 1
- 210000001008 atrial appendage Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000004375 bundle of his Anatomy 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000011443 conventional therapy Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 1
- 229960004166 diltiazem Drugs 0.000 description 1
- 229960002994 dofetilide Drugs 0.000 description 1
- IXTMWRCNAAVVAI-UHFFFAOYSA-N dofetilide Chemical compound C=1C=C(NS(C)(=O)=O)C=CC=1CCN(C)CCOC1=CC=C(NS(C)(=O)=O)C=C1 IXTMWRCNAAVVAI-UHFFFAOYSA-N 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 210000004177 elastic tissue Anatomy 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 229920000295 expanded polytetrafluoroethylene Polymers 0.000 description 1
- 210000000630 fibrocyte Anatomy 0.000 description 1
- 230000009795 fibrotic process Effects 0.000 description 1
- 229960000449 flecainide Drugs 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 210000001308 heart ventricle Anatomy 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229960004053 ibutilide Drugs 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000000954 inflammatory inducer Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 210000004971 interatrial septum Anatomy 0.000 description 1
- 208000021803 junctional tachycardia Diseases 0.000 description 1
- 238000000608 laser ablation Methods 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000007620 mathematical function Methods 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000028161 membrane depolarization Effects 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 229960002237 metoprolol Drugs 0.000 description 1
- IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 210000000651 myofibroblast Anatomy 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000002428 photodynamic therapy Methods 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 229960000244 procainamide Drugs 0.000 description 1
- REQCZEXYDRLIBE-UHFFFAOYSA-N procainamide Chemical compound CCN(CC)CCNC(=O)C1=CC=C(N)C=C1 REQCZEXYDRLIBE-UHFFFAOYSA-N 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 229960000203 propafenone Drugs 0.000 description 1
- JWHAUXFOSRPERK-UHFFFAOYSA-N propafenone Chemical compound CCCNCC(O)COC1=CC=CC=C1C(=O)CCC1=CC=CC=C1 JWHAUXFOSRPERK-UHFFFAOYSA-N 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 229960001404 quinidine Drugs 0.000 description 1
- 230000029865 regulation of blood pressure Effects 0.000 description 1
- 210000002796 renal vein Anatomy 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 210000005245 right atrium Anatomy 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 210000003752 saphenous vein Anatomy 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 230000011218 segmentation Effects 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 229920002379 silicone rubber Polymers 0.000 description 1
- 239000004945 silicone rubber Substances 0.000 description 1
- 210000001013 sinoatrial node Anatomy 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 229960002370 sotalol Drugs 0.000 description 1
- ZBMZVLHSJCTVON-UHFFFAOYSA-N sotalol Chemical compound CC(C)NCC(O)C1=CC=C(NS(C)(=O)=O)C=C1 ZBMZVLHSJCTVON-UHFFFAOYSA-N 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 229940033134 talc Drugs 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 230000019432 tissue death Effects 0.000 description 1
- 230000008467 tissue growth Effects 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 210000004026 tunica intima Anatomy 0.000 description 1
- 210000004231 tunica media Anatomy 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 238000009834 vaporization Methods 0.000 description 1
- 230000008016 vaporization Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 210000002620 vena cava superior Anatomy 0.000 description 1
- 210000002073 venous valve Anatomy 0.000 description 1
- 229960001722 verapamil Drugs 0.000 description 1
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 1
- 229960005080 warfarin Drugs 0.000 description 1
- 230000010388 wound contraction Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M29/00—Dilators with or without means for introducing media, e.g. remedies
- A61M29/02—Dilators made of swellable material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/04—Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
- A61F2/06—Blood vessels
- A61F2/07—Stent-grafts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/24—Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body
- A61F2/2478—Passive devices for improving the function of the heart muscle, i.e. devices for reshaping the external surface of the heart, e.g. bags, strips or bands
- A61F2/2481—Devices outside the heart wall, e.g. bags, strips or bands
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/24—Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body
- A61F2/2478—Passive devices for improving the function of the heart muscle, i.e. devices for reshaping the external surface of the heart, e.g. bags, strips or bands
- A61F2/2487—Devices within the heart chamber, e.g. splints
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/848—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents having means for fixation to the vessel wall, e.g. barbs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/86—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
- A61F2/90—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M29/00—Dilators with or without means for introducing media, e.g. remedies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/24—Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2002/821—Ostial stents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/848—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents having means for fixation to the vessel wall, e.g. barbs
- A61F2002/8483—Barbs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2220/00—Fixations or connections for prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2220/0008—Fixation appliances for connecting prostheses to the body
- A61F2220/0016—Fixation appliances for connecting prostheses to the body with sharp anchoring protrusions, e.g. barbs, pins, spikes
Definitions
- Cardiac arrhythmia affects millions of people worldwide and is broadly defined as an abnormal or irregular heartbeat that may involve changes in heart rhythm, producing an uneven heartbeat, or heart rates, causing a very slow or very fast heartbeat.
- arrhythmias include bradyarrhythmias and tachyarrhythmias, both being typically ventricular or supraventricular in origin.
- Bradyarrhythmias are slow heart rhythms (e.g., less than 60 beats per minute) that may result from a diseased or failing sinoatrial (SA) node, atrioventricular (AV) node, HIS-Purkinje, or bundle branch system, as explained in further detail below.
- SA sinoatrial
- AV atrioventricular
- HIS-Purkinje or bundle branch system
- Ventricular arrhythmias are arrhythmias that begin in the lower chambers of the heart.
- supraventricular arrhythmias are arrhythmias that originate above the ventricles of the heart, such as the upper chambers (i.e., atria) or the middle region (e.g., AV node or the beginning of the HIS-Purkinje system).
- accelerated rates e.g., more than 100 beats per minute
- what is considered normal heartbeat rhythms e.g., between 60 and 100 beats per minute.
- FIG. 1 depicts a cross-sectional diagram of a normal, healthy heart 10 .
- the heart 10 is a four-chamber, double-sided pump made of muscle tissue that contracts when subjected to electrical stimulation.
- the electrical stimulation that produces a heartbeat originates in the SA node 12 , located at the junction of the superior vena cava 14 with the right atrium 16 , and spreads radially through the atria causing the muscle of the heart's upper chambers to contract and pump blood to the ventricles. From the atria, the electrical signal then converges on the AV node 18 , located in the right posterior portion of the interatrial septum.
- the impulse from the AV node 18 then passes to the bundle of HIS 20 , which branches at the top of the interventricular septum 22 and runs subendocardially down either side of the septum, and travels through the bundle branches 24 .
- the signal then passes to the Purkinje system 26 and finally to the ventricular muscle causing the lower chambers of the heart to contract and pump blood to the lungs and the rest of the body.
- the sinus node initiates the next rhythm or heart beat and the entire cycle is repeated.
- it is rate of discharge from the SA node 12 (also referred to as the normal cardiac pacemaker) that determines the rate at which the heart 10 beats.
- Atrial fibrillation represents a loss of synchrony whereby the atria quiver (beating at a rate of about 600 beats per minute) instead of beating or contracting effectively.
- the loss of atrial contraction and conduction of electrical signals from the atria to the ventricles often cause blood to pool and clot in the atria, and especially in the atrial appendages. If the clot becomes dislodged from the atrium, it can travel through the bloodstream and create a blockage in a vessel that supplies blood to the brain, resulting in stroke. It is estimated that fifteen percent of all strokes occur in people with AF, which translates to about 90,000 strokes each year in the United States alone.
- Conventional therapy or treatment options for AF include medication, AF suppression and surgery. Medication or drug therapy is generally the first treatment option employed to control the rate at which the upper and lower chambers of the heart beat.
- Conventional medications used to treat AF include beta-blockers, such as metoprolol or propanolol, and calcium-channel blockers, such as verapamil or diltiazem, which depress conduction and prolong refractoriness in the AV node.
- amiodarone ibutilide
- dofetilide propafenone
- flecainide procainamide
- quinidine quinidine
- sotalol are used to affect the electrophysiology of the heart to maintain normal sinus rhythm and can thereby terminate or, in some cases, prevent AF.
- anticoagulants or blood-thinners such as warfarin or aspirin are not designed to treat AF, these medications are often used to reduce the risk of clot formation and stroke which, as previously discussed, often occur in patient's suffering from AF.
- AF suppression frequently a second treatment option for patients with AF, may be accomplished using an implanted pacemaker to stimulate the heart in a way that preempts any irregular rhythms.
- the pacemaker stimulates or overdrives the heart at a rate slightly higher than its normal, intrinsic rate. Overdriving the heart enables the device to control the heart rate and, thereby, suppress potential episodes of AF.
- Another alternative treatment for AF is surgery.
- an electrophysiology study is first performed to characterize the arrhythmic event. This study usually includes mapping the exact locations of the electrical impulses and conduction pathways along the cardiac chambers using conventional mapping techniques. After locating the cardiac tissue that is causing the arrhythmia, the tissue is then surgically altered or removed to prevent conduction of aberrant electrical impulses in the heart.
- One example of a surgical procedure used to treat cardiac arrhythmias is the Maze procedure.
- the Maze procedure is an open-heart or percutaneous surgical procedure designed to interrupt the electrical patterns or conduction pathways responsible for cardiac arrhythmia. Originally developed by Dr. James L. Cox, the Maze procedure involves carefully forming a “maze” of surgical incisions (from which the procedure's name is derived) in both atria to prevent the formation and conduction of errant electrical impulses, while still preserving the function of the atria. The incisions channel or direct the electrical impulses along the heart to maintain synchrony of contraction between the atria and ventricles of the heart, thereby producing a normal heartbeat. In addition, resulting scar tissue generated by the incisions also prevents formation and conduction of aberrant electrical signals that cause AF, thereby eradicating the arrhythmia altogether.
- Cardiac ablation techniques typically involve the removal or destruction of cardiac tissue and the electrical pathways that cause the abnormal heart rhythm. In general, cardiac ablation is less costly, has fewer side effects and requires less recovery time for the patient compared to more invasive procedures. There are various methods by which a cardiac ablation procedure may be performed. These methods and energy modalities include cryoablation, radiofrequency (RF) ablation, laser ablation, microwave, vaporization, balloon ablation, drug elution and photodynamic therapy.
- RF radiofrequency
- an electrophysiology study is first performed to characterize the arrhythmic event and map the precise locations that exhibit the arrhythmia. Once these sites are identified, an ablation catheter is maneuvered to each of these sites and a sufficient amount of energy is delivered to ablate the tissue. As a result, the energy destroys the targeted tissue and, thus, makes it incapable of producing or conducting arrhythmia, while leaving the adjacent healthy tissue intact and functional.
- ablation procedures such as cardiac segmentation procedures
- cardiac segmentation procedures have been developed to mechanically isolate or re-direct errant electrical signals in the heart.
- These procedures typically involve forming one or more linear or curvilinear lesions in the wall tissue of the heart to segment the cardiac chambers, similar to the above-described Maze procedure.
- segmented lesions are generally formed in the atrial tissue of the heart, although accessory pathways, such as those through the wall of an adjacent region along the coronary sinus, have also been produced.
- catheter based ablation procedures are less invasive than conventional surgical procedures, there are various complications that may occur. Examples of possible complications include ablation injuries, bleeding, hematoma, pericardial effusion and cardiac tamponade, failure of the procedure, scar formation and stenosis. In addition, the time course of lesion maturation and scar formation following cardiac ablation procedures often result in delayed onset of electrical isolation and high incidence of post-operative atrial fibrillation.
- the present invention contemplates an implantable device and method for modifying conduction, electrical connection and propagation properties in a tissue and/or treating cardiac arrhythmias.
- the device comprises a structural platform made of a biocompatible material, wherein the platform may be conformable to a shape of a target tissue site.
- the platform may also include a treatment component sized and shaped to induce a fibrotic response in the target tissue.
- the treatment component may also be configured to cause sufficient fibrotic response so as to substantially eliminate cardiac arrhythmias.
- the present invention also contemplates a method of treating cardiac arrhythmias.
- the method comprises delivering a treatment device to a target site and manipulating the device to conform a shape of the device to a shape of the target site.
- the method may also include modifying a tissue makeup at the target site and allowing the modification of tissue makeup to proceed so as to induce a response that results in electrically decoupling the tissue.
- the method may further include leaving the treatment device implanted at the target site.
- the present invention contemplates a device for modifying tissue at a target tissue site of an organ, wherein the device comprises at least one deployment platform.
- the deployment platform may include a treatment component configured to induce a material tissue response at the target tissue site.
- the treatment component may also be configured to induce a material tissue response sufficient to modify local physiologic properties of the organ so as to achieve a desired therapeutic goal for the organ.
- the present invention also contemplates a method of inducing a material tissue response at a target site, wherein the method includes delivering a treatment device to the target site and ensuring contact of a treatment component of the treatment device with tissue at the target site.
- the method may also include inducing the material tissue response at the target site as a result of ensuring contact of the treatment component with the tissue and allowing the material tissue response to continue at the target site at least until a therapeutic goal is substantially achieved.
- FIG. 1 is a cross-sectional diagram of a normal, healthy heart
- FIG. 2A illustrates another embodiment of the device in accordance with the present invention
- FIGS. 2B and 2C are sectional views of other embodiments of an implanted device in accordance with the present invention.
- FIGS. 3 A- 3 C illustrate sectional views of various embodiments of an implanted device in accordance with the present invention
- FIG. 4A illustrates the various layers of a vessel
- FIG. 4B illustrates areas of high sheer at various tissue points in accordance with the present invention
- FIGS. 5A and 5B illustrate other embodiments of the device in accordance with the present invention.
- FIGS. 6A and 6B are sectional views of various embodiments of an implanted device in accordance with the present invention.
- FIG. 7 is a perspective view of an embodiment of the device in accordance with the present invention.
- FIGS. 8 A- 8 C illustrate perspective views of other embodiments of the device in accordance with the present invention.
- FIGS. 8D and 8E illustrate sectional views of various embodiments of an implanted device in accordance with the present invention
- FIGS. 9A and 9B illustrate perspective views of various embodiments of an implanted device in accordance with the present invention.
- FIGS. 10A and 10B illustrate perspective views of various embodiments of an implanted device in accordance with the present invention
- FIG. 11 illustrates a perspective view of a ring-shaped embodiment of the device in accordance with the present invention
- FIGS. 12 A- 12 C illustrate sectional views of various embodiments of an implanted device in accordance with the present invention
- FIG. 12D illustrates a perspective view of an embodiment of an implanted device in accordance with the present invention
- FIG. 12E illustrates a section view of an embodiment of a device implanted on an internal surface of a vessel in accordance with the present invention
- FIG. 12F illustrates a perspective view of an embodiment of a device implanted on an external surface of a vessel in accordance with the present invention.
- FIG. 12G illustrates a perspective view of an embodiment of an implanted device in accordance with the present invention.
- a stent-shaped device 30 may be used to treat, prevent and/or terminate arrhythmias.
- stent is not meant to be limiting but, rather, is used for reader convenience and brevity.
- the device 30 resembles an “inverse sock” fabricated from a fine netting material (e.g., Nitinol®, spring-tempered stainless steel, cloth fiber, etc.).
- the netting material may be self-expandable, causing the device 30 to tightly conform to the structure into which it is placed.
- a high spatial frequency of fine material i.e., fine fibers, elongate elements (discussed in further detail below) or strands
- This design provides the device 30 with added axial conformability and trans-axial capabilities, resulting in improved tissue adhesion and fit.
- the device or deployment platform 30 of the present invention may also be characterized by its ability to bend longitudinally and trans-axially. This capability enables the device 30 to conform to any desired biologic shape, including, but not limited to, the wall of an artery, vein, cardiac chamber or other biologic target structure.
- the device 30 may also be characterized by its ability to expand in a radial direction, and continue to conform to a shape that may change.
- the device 30 may have a maximum size, beyond which the device 30 does not expand. This configuration prevents the tissue structure 36 , into which the device 30 is placed, from growing or expanding above a predetermined size.
- one or more hollow protrusions 34 lie on an external surface of the device 30 .
- the protrusions 34 pierce or embed into the tissue 36 target site of the lumen, as illustrated in FIG. 2B.
- the protrusions may penetrate the vessel wall either partially or completely (as shown in FIGS. 2B and 2C), gaining access to any cells at any location in or on the structure.
- the protrusions may also be solid rather than hollow, as may be desirable if drug delivery is not contemplated.
- the protrusions also serve various other functions as described in further detail below.
- injection from a drug delivery balloon causes the hollow protrusions 34 to conduct the drug to the adventitial surface of the lumen or vessel.
- the drug may then cause cell death, fibrosis or inflammation, all of which may be used to combat arrhythmia depending on the type of drug used and desired tissue response.
- the device 30 of the present invention and its methods of use are designed to achieve a variety of therapeutic goals including, but not limited to, prevention, treatment and/or elimination of arrhythmias.
- Studies have shown that some forms of AF originate in the pulmonary veins 44 or coronary sinus. More specifically, it has been determined that sources of AF originate in atrial tissue that is on the surface or ingrown into the vessel as it enters the left atrium (i.e., at or near the ostium of the vessel entrance into the atrium).
- pulmonary veins 44 Although further references will be made specific to the pulmonary veins 44 , it is understood that other vessels (e.g., coronary sinus, aorta, abdominal aorta, pulmonary artery, atrium, cerebral vessels, etc.) are also included within the scope of the present invention.
- vessels e.g., coronary sinus, aorta, abdominal aorta, pulmonary artery, atrium, cerebral vessels, etc.
- the device 30 When positioned at this target site, the device 30 , preferably in an expanded state, eliminates or neutralizes the electrical activity and conductivity of the atrial cells on the pulmonary vein so that AF stimulation is either prevented (by ablating the atrial cells) or the impulses are prevented from propagating into the atrium. In principle, it is distortion of the anatomy, such as the ostium, by a luminal or extra-luminal device 30 that permits sclerosis, cell death, scar formation, mechanical injury, laceration or any combination of these results to attack impulse stimulation and conduction.
- atrial tissue ablation methods It is understood that other tissue modification and ablation methods though not specifically disclosed herein are also included within the scope of the claimed invention.
- the device 30 (with or without grasping members, as discussed in further detail below) is radially expanded, for example via self-expansion and/or balloon expansion, in the lumen or outside the lumen (e.g., on the adventitia) of the pulmonary vein 44 .
- the device 30 may be expanded on an endocardial 40 or epicardial 42 surface of the heart. Expanding the device 30 sufficiently beyond the normal diameter of the pulmonary vein 44 causes the vessel to severely stretch, which induces cellular changes that alter the biologic behavior of the tissue 36 .
- the fine network of blood vessels called the “vasa vasorum,” which are located on the outer surface of many blood vessels and supply the vessel wall itself with blood, are subsequently compressed by this over-stretching, resulting in fibrosis.
- This vessel over-stretch may further produce tissue/vessel ischemia and other tension effects that may also induce fibrosis.
- the fibrosis may be induced by many mechanisms including, but not limited to, growth factors (Hypoxia Inducible Factor-1 alpha (HIF-1alpha), Vascular Endothelial Growth Factor (VEGF), etc.) and cytokines.
- Vessel over-stretch or other mechanical tissue change, is accomplished initially by deployment of the device 30 .
- continued or chronic over-stretch may be achieved by simply maintaining the oversized device 30 within the vessel.
- the over-stretch itself may also be enough to induce adventitial and/or medial fibrosis simply due to the stretch process.
- the fibrosis induced by the device 30 may be several-fold.
- the fibrosis may serve to mechanically prevent organ or gross body expansion.
- the structural component of the device 30 may be tailored to expand only to a certain degree. Fibrosis formed in the tissue 36 functions to tightly attach or “glue” the device 30 to the tissue.
- the fibrosis serves to anchor the tissue of interest to the supporting structure/device 30 , and even integrate the device completely into the tissue. As such, further expansion of the biological structure is prevented due to the mechanical properties of the device 30 and due to the fibrosis itself (which may develop and grow to contain collagen that will further inhibit mechanical expansion).
- the fibrotic response from the expandable device 30 may enable the tissue 36 to retain sufficient pliability to maintain normal tissue (or body organ) function, yet increase its overall structural strength.
- fibrosis may be induced to strengthen the wall of a cardiac ventricle when the device 30 is placed on the inside of the chamber/structure, while still allowing the ventricle to contract, move and fulfill its normal function.
- the fibrosis also prevents ventricular expansion beyond a certain predetermined size.
- the material make-up of this type of pliable fibrous tissue comprises more elastin and other pliable materials than collagen.
- the fibrotic response may be stimulated to a severe degree causing a process of negative remodeling or contraction.
- This response well known by those skilled in the art, results in natural scar formation that promotes wound contraction or shrinkage.
- the amount of fibrosis contraction may be controllable, via device materials, structure and other components, and may range from no remodeling to a small/medium/large amount of negative remodeling (resulting in contraction). This would be of particular use in preventing expansion of an aneurysm, as in the abdominal aorta or the cerebral vessels.
- the degree of remodeling is based upon the pre-selected application and desired response.
- the device 30 may be configured to induce elastance in the tissue or an elastin-rich fibrosis (e.g., stimulate elastin synthesis and cellular growth) that is quite flexible and visco-elastic.
- the device may be configured to stimulate growth of densely packed collagen that may mimic the need for such bioabsorbable tissue 36 .
- the induced tissue 36 is quite inelastic and, thus, prevents tissue and device expansion.
- inducing a simultaneous combination of elastin and collagen may simulate any range of mechanical properties for both tissue 36 and device 30 .
- the device 30 may be configured to control the biologic features of the fibrosis and its cellularity. For example, a highly cellular scar may be formed or, alternatively, less cellular tissue may be produced due to device structure and/or materials.
- the device 30 may be coated with a material to stimulate less collagen or elastin growth and increased glycose-aminoglycan and other components of extra cellular matrix production.
- Inflammation induced fibrosis may be accomplished using an embodiment of the device 30 having prongs or tissue grabbers 34 that penetrate partially into or completely through the vessel.
- a chemical irritant located on the surface of the prongs 34 causes the desired inflammation and, thereby, induces fibrosis in the atrial tissue 36 .
- the fibrosis occurs in and around the three-dimensional structure and, thus, it is the structural configuration of the device 30 that guides/determines the eventual fibrosis configuration.
- the device 30 may be configured in any arbitrary shape, size and density and may include one or more of a variety of chemicals/agents/substances. Alternatively, the device 30 may be placed only against the interior surface and tissue ablation may still occur on the outer surface of the biologic structure.
- the tips of the prongs 34 are coated with a chemical irritant, the remainder of the stalk of each prong 34 being uncoated and, thus, inactive.
- the interior of the prongs 34 may house additional chemical irritant that elutes out into the outer regions of the vein, thereby gradually inducing a fibrotic response that prevents initiation or propagation of the arrhythmia.
- chemical irritants include, but are not limited to, metallic copper, zinc, talc, polymers, drug-eluting polymers, tetracycline or other fibrosis-inducing substances.
- a toxic substance may also be used to induce fibrosis.
- the substance is released into the tissue 36 by the device 30 , via a delivery device and/or any of the previously disclosed methods, and either kills atrial cells or prevents their depolarization and/or conduction.
- the resulting fibrosis or scarring inhibits cell stimulation and/or impulse propagation and, thereby, prevents or terminates the arrhythmia.
- Examples of toxic substances include, but are not limited to, metallic copper, zinc, polymers, poly-lactic acid, poly-glycolic acid, tetracycline, talc or any other chemicals/agents/substances capable of fibrosis induction.
- a conventional stent-shaped device 30 near the atrial entrance of the pulmonary vein 44 , or entrance of any other vessel generally distorts the ostium-atrial entrance geometry in a radial (i.e., outward, trans-axial) direction.
- this configuration may be effective in attacking arrhythmias since cell/tissue death or fibrosis may successfully interrupt the conduction/stimulation of AF.
- an alternate embodiment of the device 30 of the present invention includes one or more outwardly flared portions 46 .
- the flared end 46 When positioned within a patient, the flared end 46 is located at or near the ostium or vein-atrial interface.
- this device configuration also draws tissue into the ostium and, in so doing, causes the cells to cease conduction, either by death or fibrosis.
- distortion of the ostium prevents propagation or conduction of impulses into the atrial tissue 36 and, thereby, terminates arrhythmias.
- the flared end 46 of the device 30 may further include a lip or ring 48 that extends out into the atrium 50 .
- the ring 48 functions to prevent conduction and/or generation of impulses beyond the ostium and, in so doing, terminates AF or prevents its conduction into the atrial tissue.
- the device 30 of the present invention functions to stretch not only the vein, but also the ostium. This stretch causes tension in the vessel wall and compression of blood supply in either capillary form or vasa vasorum. The resulting compression may further produce tissue ischemia and other tension effects and induce fibrosis and/or collagen/matrix formation to interrupt electrical impulse generation and conduction. As disclosed in further detail below, toxic or inflammatory agents may also be included with the device of the present invention to prevent, treat and/or terminate arrhythmias.
- the device 30 of the present invention may also be used to stimulate proliferation of cells in the adventitial or outside region of a vein or artery, where electrically active cells reside and/or conduction occurs.
- An illustration of the various tissue layers of an artery/vein is shown in FIG. 4.
- the vessel 52 includes three layers or “tunics.”
- the tunica intima 54 comprises an inner endothelial cell layer 56 (i.e., the endothelium), a subendothelial connective tissue 58 and a layer of elastic tissue 60 (i.e., the elastica interna).
- the tunica media 62 comprises smooth muscle and the tunica adventitia 64 comprises connective tissue.
- Cell proliferation stimulated by the device 30 and/or methods of the present invention, consists of fibrous tissue, fibroblasts, myofibroblasts and other extra-cellular matrix elements that serve to isolate the electrically active cells that cause the arrhythmia. As such, cells are not necessarily killed or injured, as with ablation techniques. Moreover, the proliferation and stimulation of fibrosis (including fibroblasts, fibrocytes, collagen and extra cellular matrix formation) occurs throughout the vessel wall (i.e., a transmural effect), including within the intima 54 .
- tension can cause collapse of arterial or venous vasa vasorum, thereby making the vessel ischemic. Also, if the tension is too high, injury or laceration (small to large, depending on the tension applied) to the vessel may occur. However, it has been shown that such tension may also actually stimulate proliferation of fibrous tissue. Therefore, by controlling the amount of tension or injury (with or without tissue laceration), the degree of fibrosis and proliferation can also be controlled. Moreover, the tissue proliferation is typically proportional to the tension and injury created.
- the device 30 of the present invention carefully controls the injury and, thus, does not stimulate such stenosis.
- the transmural effects of the device 30 and associated methods may affect the adventitia with fibrosis; however, the inner lumen remains relatively unaffected.
- the mechanical and/or structural support offered by the implant 30 further limits or eliminates the problem of fibrosis restricting the lumen (which generally also induces stenosis).
- high shear at sharp points can be placed at various points on the tissue 36 using the device 30 , as shown in FIG. 4A, thus creating localized fibrosis that extends transmurally from intima 54 to adventitia 64 .
- These focal areas can then be used to create conduction isolation/blocks, due to the non-arrhythmic/non-conductive nature of the fibrous tissue and matrix.
- the device 30 can also be used to induce fibrosis by inflammation induction. It has been determined that subsequent healing of the inflammation is a long-term cause of fibrosis.
- This inflammation can be purely mechanical (e.g., stress; tension) or chemical (e.g., copper and/or zinc coating; inflammatory agent coating).
- a chemical agent could also be delivered to the target site by a local delivery mechanism (such as a local drug delivery balloon) prior to or following device delivery. The body's response to the inflammation is to attack the inflammation, thereby producing excess interstitial fibrous tissue which prevents conduction or generation of irregular signals.
- the present invention may also be used to induce calcification of the adventitial region within a vessel, such as the pulmonary vein 44 .
- the calcification process functions to harden soft tissue which interrupts electrical conduction of atrial impulses and, thus, prevents AF impulses from spreading to the atrium.
- calcification of the coronary sinus can also be performed, in the event that the coronary sinus is involved in the arrhythmic circuit. In general, calcification may be induced in practically any tissue region exhibiting arrhythmia.
- One method of inducing calcification is to take blood directly from a patient and inject it into the vascular wall.
- the blood may be concentrated, for example, by methods of centrifugation or sedimentation by gravity. Since the red blood cells are the apparent inducers of calcification, the blood is first concentrated to separate out these red blood cells. Next, a sufficient amount of red blood cells are then injected directly into the wall of the vessel. Consequently, the tissue 36 becomes relatively hardened or inflexible due to calcification, thereby suppressing or terminating irregular rhythm conduction.
- the above-discussed injection may be accomplished using a local drug delivery catheter such as the Infiltrator (manufactured by Boston-Scientific Corp.).
- the Infiltrator has small needles capable of delivering injectate through the needles and into the wall of the vessel. However, care should be taken so that the needle does not dissect the vessel wall during the injection process. As such, small dissections may be more beneficial and induce a higher calcific volume compared to larger dissections.
- the device 30 may also be used to prevent or slow growth/expansion of aneurysms.
- the device 30 creates fibrosis and collagen deposition and promotes cellularity of the aneurysms to hemodynamically stabilize them, thereby preventing growth and rupture. This is accomplished by initially generating a temporary inflammatory reaction that heals with a fibrotic layer. The resulting fibrosis contains cellularity, a feature that sustains the fibrosis, attaches the device 30 to the artery wall, and provides for long-term stabilization of the biologic-technologic hybrid combination.
- This embodiment of the device 30 comprises a percutaneous implant that expands, either through a self-expanding mechanism (similar to those described previously and in further detail below) or via a balloon-expanding mechanism.
- the device 30 may further exhibit excellent longitudinal and trans-axial flexibility, enabling it to optimally conform to the vessel wall.
- the device 30 provides a supporting structure that effectively presses the device 30 against the wall of the aneurysm, preventing both expansion and rupture of the aneurysm.
- the fibrosis serves to irreversibly attach the device to the vessel wall.
- the device 30 may be coated with a chemical (similar to those described previously and in further detail below) that induces an inflammatory response.
- the device 30 may also include a large structural component combined with a fine netting or mesh. This configuration may provide improved coverage of the internal surface of the aneurysm. As such, when the inflammatory material is pressed against or contacts the intima of the vessel, this induces a subsequent inflammatory response. Additionally, the material may be made to expand only to a certain point, and then become quite stiff/rigid, thereby limiting further expansion of the device 30 and/or aneurysm.
- the material structure or configuration of the device 30 alone may be sufficient to stimulate a thickened response (e.g., cellularity) or create tension that makes the adventitia ischemic.
- a thickened response e.g., cellularity
- these mechanisms may be similar to those by which a stent induces fibrosis and neointimal thickening in a vessel.
- the device 30 simply needs to be pressed against the wall of the vessel to induce the desired fibrotic response.
- it may be the intimal placement of the mesh/inflammatory coating of the device 30 that generates the desired adventitial inflammatory response.
- the above-described device 30 may be used to treat a variety of aneurysms, such as abdominal aortic aneurysms, cerebral aneurysms and all peripheral aneurysms of arterial or venous structures.
- the device 30 may be positioned in the abdominal aorta of a patient with a small to moderate sized aneurysm.
- This device 30 may also be configured to prevent radial expansion both by mechanical features of the strut and also by the fibrous structure of the induced tissue response.
- the device 30 fibroses the aortic wall, gives it a cellular nature, thickens the wall, increases the structural integrity of the organ/abdominal aorta at the aneurysm site, attaches to the wall and/or prevents expansion.
- the aneurysm is thus “frozen” in size and cannot continue to grow (i.e., limited device expansion also limits aneurysm expansion). This result eliminates the need for future surgical repair and, further, is prophylactic for aneurysm growth.
- cerebral aneurysms may also be treated using the device 30 of the present invention.
- the device 30 generally smaller in size, strengthens the structural integrity of the organ at the aneurysm site and, thus, prevents both expansion and rupture due to the resulting thickened wall structure (i.e., cellularity).
- the device 30 of the present invention may be used in a variety of additional applications.
- the device 30 may be placed in a vein graft (e.g., saphenous vein graft) that is beginning to degenerate.
- the device 30 functions to “reline” the vein graft with a layer of device material and/or tissue 36 .
- the density of material determines the amount of cellularity and neointima produced.
- the device 30 may be placed in a vein to “shrink” the venous size, thereby restoring venous valve patency.
- the device 30 is positioned to encircle the entire atrium, thus providing full internal support as the fibrous tissue develops and restoring/maintaining normal atrial contraction.
- the device 30 may be positioned internally of the heart as one or more atrial rings. Fibrous tissue growth induced by the device 30 may not only prevent undesired atrial expansion but, further, may terminate AF.
- the internally implanted device 30 promotes formation of an endocardial encircling ring that prevents ventricular infarct expansion and, in some instances, ventricular remodeling.
- the device 30 of the present invention may be an elastic band, passive (i.e., requires no energy) and percutaneously implantable device 30 that functions as an arterial shock absorber when implanted at a target site.
- the device 30 modifies the elasticity of that structure (i.e., the pressure-volume relationship of the structure in a fixed manner that may be linear, or any other simple mathematical function).
- the device 30 of the present invention when elastic and placed in the aorta or great vessels, restores elasticity (as previously described and discussed in further detail below) to aging cardiovascular systems that have become stiff, rigid, and cause hypertension. If the applied pressure-volume relationship of the implantable device 30 is appropriately nonlinear, the device becomes a “blood pressure regulator.” As such, the device 30 allows any blood pressure up to a pre-defined limit, but prevents higher blood pressures than that limit by expanding to accommodate the volume of ejected blood and prevent pressure rises. By restoring a capacitive vector to the central circulation, the device 30 actually lowers blood pressure without pharmacology.
- the device 30 functions as a passive, hydraulic system that absorbs volume in proportion to pressure and has a rapid frequency response.
- the device 30 is configured as a scaffold (with, for example, a stent-like configuration) that grows into the artery and becomes part of the vessel.
- the device 30 functions as an “arterial shock absorber” after implant.
- the following are several examples of various embodiments of the device 30 used to treat hypertension.
- the stent-like device 30 includes two concentric, tubular-shaped members 68 , 70 that function as a shock-absorber to blood flow/pressure.
- the inner member 68 of the device 30 compresses against the outer member 70 , thereby absorbing, partially or totally, the volume of ejected blood to maintain normal pressure within the system.
- the amount of compression is proportional to the pressure; however, nonlinear compression-pressure relationships may also be desirable (as described above) to generate unique properties, such as blood pressure regulation.
- the volume of fluid/blood absorbed may be up to 20% or more of the stroke volume.
- the device 30 may be a fiber band on a circumferential support structure that stimulates elastin growth. As shown in FIGS. 8 C- 8 E, the device 30 may be partially or completely covered with elastin or an elastin epitope. In this configuration, the device 30 , in essence, functions to restore the capacitive vector to the vessel/organ 36 . For example, as the heart ejects a bolus of blood into, for example, the aorta, the elastin expands to partially accept the volume, thereby preventing the blood pressure from rising as high as would be the case were the vessel rigid (i.e. without the device 30 ). In general, the amount of expansion is proportional to the pressure.
- the device 30 may be fabricated from a variety of materials and configured into various designs.
- the device 30 may be completely elastic, due to its material and/or structural characteristics.
- the device 30 may be elastic and include pores that promote cellular in growth so that the device 30 becomes a living structure within the body.
- the device 30 By restoring the elastic pressure-volume capacitive relationships, the device 30 is useful as a passive (e.g. non-powered), non-pharmacologic method for treating heart failure. This is true not only because blood pressure is lowered, but also because the energy of the failing heart is more efficiently coupled to the arterial system via the compliant nature of the device 30 . Thus, if the device 30 functions with minimal energy loss, then the energy is more efficiently coupled.
- one or more springs 72 are located between the two membranes 68 , 70 of the device 30 .
- the springs enable the device 30 to function with minimal energy loss such that the resulting system actually conserves energy, an important feature/attribute for cases with failing hearts.
- the biocompatible device 30 includes inflammation inducing features (e.g., structural, chemical, etc.) either on the entire device 30 or on a portion of the device 30 .
- the inflammation may further induce fibrosis which functions to “glue” the device 30 to the inside of an artery or other organ.
- the device 30 may also be configured to function as a bladder-like system.
- This system may include compressibility features that decrease volume with increasing blood pressure.
- the device 30 may include certain features or mechanisms that are externally programmable.
- features/mechanisms include, but are not limited to, variable compliance, variable compressibility, and variable expandability.
- one or more Nitinol® springs of the device 30 may be heated externally in order to change the spring constant. Changing the spring constant may increase (or decrease, depending on the type of change) the amount of device compressibility to that which is more proportional to the hypertension.
- the ability to transcutaneously heat Nitinol® may yield other programmable features, not disclosed herein but known to those skilled in the art, which are also included within the scope of the claimed invention.
- the device 30 may include feedback capabilities.
- the device 30 of the present invention may measure and transmit pressure readings to another implantable device, such as a biventricular pacing system. This configuration permits literal and real-time feedback to optimize energy transfer and heartbeat within the system.
- the device 30 is generally a passive, non-powered device.
- these communication or sensing features of the device 30 may require a source of power in order to properly function. In one embodiment, this can be accomplished via the compression/expansion capabilities of the device 30 . As the blood pressure causes the device 30 to compress/expand, this energy, in turn, can be captured to generate electrical energy which can then be transferred to power the system. Alternate energy generating systems and means, not disclosed herein but known to those skilled in the art, may also be used and are also included within the scope of the claimed invention.
- an alternate embodiment of the implantable device 30 in accordance with the present invention includes at least one elongate element 32 and one or more protrusions or grasping members 34 that extend into or through tissue 36 .
- the device 30 comprises a sterile biocompatible material and may be percutaneously or surgically implanted on either an endocardial or epicardial surface of the heart.
- the device 30 may be implanted within a lumen of the heart. The size and configuration of the device 30 , including the materials from which it is made, are tailored to properly conform to tissue requirements and desired device-induced results.
- the invention as disclosed herein generally refers to the heart, other body organs and cavities, such as pulmonary veins, coronary artery, coronary vein, renal artery, renal vein, aorta, cerebral vessels, coronary sinus or other similar cavities/organs, are also included within the scope of the present invention.
- an alternate embodiment of the device 30 of the present invention may include a plurality of elongate elements 32 configured to form a mesh-shaped device 30 .
- This device 30 configuration not only increases the surface area of the device 30 that contacts tissue 36 , but may also enhance the structural integrity, flexibility and tissue adhesion characteristics of the device 30 .
- the elongate elements 32 may be rod-shaped to form a type of fiber.
- the fiber-shaped element 32 may be used alone or in combination with other devices.
- the fiber-shaped element 32 may be combined with a fabric or net 38 , thereby functioning as a structural component of the resulting device 30 .
- the device 30 produces the desired fibrotic response through proper tissue contact, shown in FIG. 8D, and/or by becoming integrated within, the tissue 36 , as shown in FIG. 8E. Additional details concerning device structure and tissue response are described in further detail below.
- One or more of the elongate elements 32 or simply portions of the elongate elements 32 may also be configured to an increased thickness/diameter, which may provide increased strength and structural integrity to the overall device 30 .
- Additional device 30 configurations including, but not limited to, ribbon-shaped, spherical, cubical, tubular, rod-shaped, net-shaped, ring-shaped, sheet-shaped and woven, including combinations thereof, are also within the scope of the claimed invention.
- the grasping members 34 of the present invention are generally designed to be pushed into and attached to tissue 36 , such as muscle, as described in further detail below. These grasping members 34 anchor the device 30 to the tissue 36 and, thus, prevent the device 30 from slipping/dislodging or causing embolization within the patient. As such, the grasping members 34 may be configured as darts, studs, barbs, prongs, pointed structures, capped rods and other designs for secure attachment to and/or permanent placement within tissue 36 .
- a variety of methods may be used to urge the grasping members 34 into the tissue 36 .
- Examples of such methods include, but are not limited to, a radially expanding balloon, a self-expanding device 30 (due to material characteristics of the device 30 or structural characteristics, such as internal struts), an expanding tool, or mechanical force by a physician.
- the device 30 illustrated in FIGS. 6 A- 8 E includes at least one grasping member 34 designed to penetrate partially or completely through tissue 36
- the device 30 may also be configured to include no grasping members 34 .
- Tissue adhesion or attachment may be accomplished via structural or chemical characteristics of the device 30 .
- the device 30 may be configured to conform and, thereby, adhere to an internal or external area of a body cavity.
- the device 30 may be fabricated from porous materials that promote tissue adhesion and subsequent biological anchoring. Permanent cellular in-growth may further transform the device 30 into a living structure. As such, the living nature of the device 30 permits it to become integrated and thereby last for long periods of time within the body.
- porous materials used with the device 30 of the present invention include, but are not limited to, ceramics, alumina, silicon, Nitinol®, stainless steel, titanium, porous polymers, such as polypropylene, ePTFE, silicone rubber, polyurethane, polyethylene, acetal, nylon, polyester, and any combination of such materials. Although these materials (and others not specifically described, but included in the scope of the claimed invention) may not be inherently porous, various manufacturing and processing techniques may be used to give the materials the desired porosity characteristics.
- the device 30 is made of a conductive material, such as stainless steel.
- a conductive material such as stainless steel.
- Alternative biocompatible materials including, but not limited to, metals, ceramics, plastics, bioabsorbable materials, bioresorbable materials, biostable materials, absorbable materials, non-absorbable materials or biomaterials, either alone or in various combinations, may also be used.
- the device 30 of the present invention is used to treat, prevent and/or terminate arrhythmias.
- the device 30 is made of a conductive material, such as a metal, and functions as a voltage clamp to short circuit an arrhythmia.
- the grasping members 34 of the device 30 are pushed into the target cardiac tissue 36 .
- a single device 30 or multiple devices 30 may be placed over a portion or circumferentially around a cardiac chamber, such as the atrium or ventricle, depending on the type and location of the arrhythmia.
- the devices 30 may be placed in parallel (i.e., multiple equatorial bands, shown in FIGS. 9A and 9B) or combined to form equatorial and polar rings, shown in FIGS. 10A and 10B, respectively.
- the metallic properties of the device 30 particularly the grasping members 34 which are also made of metal, cause the device 30 to hold the intramyocardial tissue 36 at the same isoelectric potential across the entire device 30 .
- the isoelectric potential also extends through the entire transmural muscle. As such, since all device-contacted muscle must be isoelectric, the device 30 short-circuits the arrhythmia.
- arrhythmias that may be short-circuited by the device 30 include, but are not limited to, atrial fibrillation, reentrant supraventricular tachycardia (SVT), ventricular tachycardia (VT) and Junctional Tachycardia.
- SVT reentrant supraventricular tachycardia
- VT ventricular tachycardia
- Junctional Tachycardia reentrant supraventricular tachycardia
- atrial fibrillation reentrant supraventricular tachycardia
- VT ventricular tachycardia
- Junctional Tachycardia junctional Tachycardia
- the device 30 of the present invention may also be used to isolate localized sources of arrhythmias. As previously discussed in the Background of the Invention, some arrhythmias may be triggered or maintained by a single focus of automatic firing. To prevent the aberrant signal from propagating throughout the cardiac muscle, the elongate member 32 is configured into a generally ring-shaped device 30 , as illustrated in FIG. 11. However, it is understood that other device configurations optimized to isolate the particular arrhythmia at a specific tissue site may also be used and are hereby included within the scope of the claimed invention.
- the device 30 is then positioned to contact the tissue 36 and surround that portion of muscle from which the arrhythmia originates.
- the device 30 may be located on a portion of either an endocardial 40 or epicardial 42 surface of an atrium, ventricle or vessel (such as a pulmonary vein), shown in FIGS. 12A, 12B, 12 C and 12 D.
- the device 30 may be positioned to surround one or more of the pulmonary veins 44 on either an endocardial 40 or epicardial 42 surface of the heart.
- the device 30 may be placed on an internal surface or an external surface of a pulmonary vein 44 .
- the metallic nature of the device 30 together with its tissue-contacting characteristics create a block thereby preventing conduction of the impulse beyond the confines of the device 30 and, ultimately, short-circuiting the arrhythmia.
- one or more biologics, drugs or other chemicals/agents may also be included with the device 30 .
- the chemical may be bound, for example, to at least a portion of the surface and/or interior of the elongate members 32 and/or grasping members 34 of the device 30 .
- the grasping members 32 may be hollow allowing the chemical to elute from the hollow area of the grasping members 34 and into the tissue 36 .
- the device 30 is fabricated from porous materials (as discussed above), the chemical may be contained within and released from the pores and into the tissue 36 .
- the chemical/agent is released into the myocardial tissue 36 or simply interfaces with the tissue 36 as it contacts the device 30 .
- the chemical which may be a coating that is bioabsorbable (or biostable), dissolves or erodes and disappears over time.
- the chemical promotes formation of an endothelial lining and, eventually, a neointimal layer, thereby encasing the device within the tissue.
- the chemical may be an anti-thrombotic material that functions to prevent clot formation and/or embolization from the implanted device 30 .
- the chemical may depress or prevent conduction of aberrant impulses, affect the electrophysiology of the heart to maintain normal sinus rhythm, act as a therapeutic agent, terminate arrhythmias or induce other desired tissue and system responses.
- these chemicals/agents include, but are not limited to, blood, copper, zinc, nickel, polylactic acid, polyglycolic acid, heparin, platelet glycoprotein IIb/IIa inhibiting agent, tetracycline, lidocaine, starch, paclitaxel, adriamycin, alcohol, fibrosis inducing agents, inflammatory inducing agents, anticoagulants, polymers, drug-eluting polymers, macrophage chemoattractant protein, chemoattractants, therapeutic drugs and other agents/chemicals.
- the device 30 and methods of use of the present invention effectively reduce pain, infections and postoperative hospital stays. Further, the various treatment methods also improve the quality of life for patients.
Landscapes
- Health & Medical Sciences (AREA)
- Cardiology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Life Sciences & Earth Sciences (AREA)
- Vascular Medicine (AREA)
- Transplantation (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Anesthesiology (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Prostheses (AREA)
- Surgical Instruments (AREA)
- Media Introduction/Drainage Providing Device (AREA)
- Electrotherapy Devices (AREA)
Priority Applications (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/192,402 US20030055491A1 (en) | 2001-07-06 | 2002-07-08 | Anti-arrhythmia devices and methods of use |
| US10/665,785 US20040133260A1 (en) | 2001-07-06 | 2003-09-17 | Lumenal vascular compliance device and method of use |
| US11/551,670 US8579955B2 (en) | 2001-07-06 | 2006-10-20 | Anti-arrhythmia devices and methods of use |
| US14/065,220 US20140052169A1 (en) | 2001-07-06 | 2013-10-28 | Anti-Arrhythmia Devices And Methods Of Use |
| US14/960,266 US20160082234A1 (en) | 2001-07-06 | 2015-12-04 | Anti-Arrhythmia Devices And Methods Of Use |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30357301P | 2001-07-06 | 2001-07-06 | |
| US10/192,402 US20030055491A1 (en) | 2001-07-06 | 2002-07-08 | Anti-arrhythmia devices and methods of use |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US10/665,785 Continuation-In-Part US20040133260A1 (en) | 2001-07-06 | 2003-09-17 | Lumenal vascular compliance device and method of use |
| US11/551,670 Continuation US8579955B2 (en) | 2001-07-06 | 2006-10-20 | Anti-arrhythmia devices and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US20030055491A1 true US20030055491A1 (en) | 2003-03-20 |
Family
ID=23172707
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US10/192,402 Abandoned US20030055491A1 (en) | 2001-07-06 | 2002-07-08 | Anti-arrhythmia devices and methods of use |
| US11/551,670 Expired - Fee Related US8579955B2 (en) | 2001-07-06 | 2006-10-20 | Anti-arrhythmia devices and methods of use |
| US14/065,220 Abandoned US20140052169A1 (en) | 2001-07-06 | 2013-10-28 | Anti-Arrhythmia Devices And Methods Of Use |
| US14/960,266 Abandoned US20160082234A1 (en) | 2001-07-06 | 2015-12-04 | Anti-Arrhythmia Devices And Methods Of Use |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US11/551,670 Expired - Fee Related US8579955B2 (en) | 2001-07-06 | 2006-10-20 | Anti-arrhythmia devices and methods of use |
| US14/065,220 Abandoned US20140052169A1 (en) | 2001-07-06 | 2013-10-28 | Anti-Arrhythmia Devices And Methods Of Use |
| US14/960,266 Abandoned US20160082234A1 (en) | 2001-07-06 | 2015-12-04 | Anti-Arrhythmia Devices And Methods Of Use |
Country Status (6)
| Country | Link |
|---|---|
| US (4) | US20030055491A1 (fr) |
| EP (2) | EP1406559A1 (fr) |
| JP (2) | JP2004533890A (fr) |
| AU (1) | AU2002327219B2 (fr) |
| CA (1) | CA2453210A1 (fr) |
| WO (1) | WO2003003948A1 (fr) |
Cited By (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040167598A1 (en) * | 2002-11-08 | 2004-08-26 | Margolis James R. | Device and method for electrical isolation of the pulmonary veins |
| US20050131503A1 (en) * | 2003-11-17 | 2005-06-16 | Synergio Ag | Device, a kit and a method for treatment of disorders in the heart rhythm regulation system |
| US20050234540A1 (en) * | 2004-03-12 | 2005-10-20 | Nmt Medical, Inc. | Dilatation systems and methods for left atrial appendage |
| WO2006042246A2 (fr) | 2004-10-08 | 2006-04-20 | Syntach Ag | Generation de cicatrice en deux etapes pour le traitement de la fibrillation auriculaire |
| US20060116548A1 (en) * | 2004-11-03 | 2006-06-01 | Cook, Incorporated | Methods for treating valve-associated regions of vascular vessels |
| US20060178725A1 (en) * | 2004-03-02 | 2006-08-10 | Sinus Rhythm Technologies, Inc. | Electrical conduction block implant device |
| US20060241690A1 (en) * | 2004-03-19 | 2006-10-26 | Aga Medical Corporation | Multi-layer braided structures for occluding vascular defects and for occluding fluid flow through portions of the vasculature of the body |
| US20070255389A1 (en) * | 2006-04-26 | 2007-11-01 | The Cleveland Clinic Foundation | Apparatus and method for treating cardiovascular diseases |
| US20070265656A1 (en) * | 2004-03-19 | 2007-11-15 | Aga Medical Corporation | Multi-layer braided structures for occluding vascular defects |
| US20080200945A1 (en) * | 2004-03-19 | 2008-08-21 | Aga Medical Corporation | Device for occluding vascular defects |
| US20080312676A1 (en) * | 2005-05-17 | 2008-12-18 | Jan Otto Solem | Device And Kit For Treatment Of Disorders In The Heart Rhythm Regulation System |
| US20090062841A1 (en) * | 2004-03-19 | 2009-03-05 | Aga Medical Corporation | Device for occluding vascular defects |
| US20090171445A1 (en) * | 2003-03-03 | 2009-07-02 | William Swanson | Electrical Conduction Block Implant Device |
| US20090210048A1 (en) * | 2008-02-18 | 2009-08-20 | Aga Medical Corporation | Stent/stent graft for reinforcement of vascular abnormalities and associated method |
| US20100016877A1 (en) * | 2006-05-17 | 2010-01-21 | Syntach Ag | Controllable Device, A Kit And A Method For Treatment Of Disorders In The Heart Rhythm Regulation System |
| WO2010033725A3 (fr) * | 2008-09-20 | 2010-06-10 | Steven Craig Anderson | Appareil et procédé pour l’adhérence d’un tissu |
| US20100268323A1 (en) * | 2006-06-08 | 2010-10-21 | Daniel Sullivan | Inflammation Accelerating Prosthesis |
| US20100305603A1 (en) * | 2007-10-17 | 2010-12-02 | Stevan Nielsen | Shape-Changing Medical Device, Kit, Method Of Production, And Method Of Use |
| US20110015722A1 (en) * | 2005-09-09 | 2011-01-20 | Edwards Lifesciences Corporation | Device and method for reshaping mitral valve annulus |
| WO2012016886A3 (fr) * | 2010-07-26 | 2012-05-10 | Hans Reiner Figulla | Implant médical pour la stabilisation endovasculaire de parois de vaisseaux et procédé de fabrication d'un tel implant |
| US20130245621A1 (en) * | 2012-03-16 | 2013-09-19 | St. Jude Medical Ab | Ablation stent and method of using an ablation stent |
| US20130317593A1 (en) * | 2000-03-27 | 2013-11-28 | Neovasc Medical Ltd. | Varying diameter vascular implant and balloon |
| US8652201B2 (en) | 2006-04-26 | 2014-02-18 | The Cleveland Clinic Foundation | Apparatus and method for treating cardiovascular diseases |
| US20140194967A1 (en) * | 2007-12-12 | 2014-07-10 | Intact Vascular, Inc. | Device and method for tacking plaque to blood vessel wall |
| US20150051708A1 (en) * | 2011-03-17 | 2015-02-19 | Microkoll Inc. | Apparatus and method for tissue adhesion |
| WO2016145391A1 (fr) * | 2015-03-11 | 2016-09-15 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Système de greffe cardiovasculaire expansible |
| US9526572B2 (en) | 2011-04-26 | 2016-12-27 | Aperiam Medical, Inc. | Method and device for treatment of hypertension and other maladies |
| US10022250B2 (en) | 2007-12-12 | 2018-07-17 | Intact Vascular, Inc. | Deployment device for placement of multiple intraluminal surgical staples |
| US10117762B2 (en) | 2007-12-12 | 2018-11-06 | Intact Vascular, Inc. | Endoluminal device and method |
| US10137013B2 (en) | 2010-05-29 | 2018-11-27 | Intact Vascular, Inc. | Endoluminal device and method |
| US10166127B2 (en) | 2007-12-12 | 2019-01-01 | Intact Vascular, Inc. | Endoluminal device and method |
| US10172729B2 (en) | 2015-10-12 | 2019-01-08 | Reflow Medical, Inc. | Stents having protruding drug-delivery features and associated systems and methods |
| US10245167B2 (en) | 2015-01-29 | 2019-04-02 | Intact Vascular, Inc. | Delivery device and method of delivery |
| US10271973B2 (en) | 2011-06-03 | 2019-04-30 | Intact Vascular, Inc. | Endovascular implant |
| US10278839B2 (en) | 2007-12-12 | 2019-05-07 | Intact Vascular, Inc. | Endovascular impant |
| US20200268279A1 (en) * | 2008-07-25 | 2020-08-27 | ResMed Pty Ltd | Method and apparatus for detecting and treating heart failure |
| US10799374B2 (en) | 2007-12-12 | 2020-10-13 | Intact Vascular, Inc. | Device and method for tacking plaque to blood vessel wall |
| US10898356B2 (en) | 2015-01-29 | 2021-01-26 | Intact Vascular, Inc. | Delivery device and method of delivery |
| US10993824B2 (en) | 2016-01-01 | 2021-05-04 | Intact Vascular, Inc. | Delivery device and method of delivery |
| US11660218B2 (en) | 2017-07-26 | 2023-05-30 | Intact Vascular, Inc. | Delivery device and method of delivery |
| WO2025188999A1 (fr) * | 2024-03-07 | 2025-09-12 | Edwards Lifesciences Corporation | Gestion de pression élevée de remplissage côté gauche |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7291165B2 (en) * | 2002-01-31 | 2007-11-06 | Boston Scientific Scimed, Inc. | Medical device for delivering biologically active material |
| US20040106952A1 (en) * | 2002-12-03 | 2004-06-03 | Lafontaine Daniel M. | Treating arrhythmias by altering properties of tissue |
| WO2005039689A2 (fr) | 2003-10-24 | 2005-05-06 | Sinus Rhythm Technologies, Inc. | Procedes et dispositifs pour la creation de bloc electrique en des sites specifiques du tissu cardiaque avec ablation de tissu cible |
| ATE409064T1 (de) * | 2004-10-13 | 2008-10-15 | Medtronic Inc | Selbstfixierende implantierbare gerüste zur verabreichung von biologischen oder pharmazeutischen substanzen |
| US7850645B2 (en) * | 2005-02-11 | 2010-12-14 | Boston Scientific Scimed, Inc. | Internal medical devices for delivery of therapeutic agent in conjunction with a source of electrical power |
| AU2007247110A1 (en) * | 2006-05-09 | 2007-11-15 | Syntach Ag | Formation of therapeutic scar using small particles |
| US20090209988A1 (en) * | 2006-05-17 | 2009-08-20 | Syntach Ag | Patient configured device, a kit and a method for treatment of disorders in the heart rhythm regulation system |
| US7815687B2 (en) * | 2007-12-18 | 2010-10-19 | Med Institute, Inc. | Method of promoting cell proliferation and ingrowth by injury to the native tissue |
| GB0804654D0 (en) | 2008-03-13 | 2008-04-16 | Smith & Nephew | Vacuum closure device |
| AU2011328926B2 (en) | 2010-11-16 | 2015-07-09 | Tva Medical, Inc. | Devices and methods for forming a fistula |
| US9226737B2 (en) * | 2011-02-04 | 2016-01-05 | University Of Massachusetts | Negative pressure wound closure device |
| US9421132B2 (en) | 2011-02-04 | 2016-08-23 | University Of Massachusetts | Negative pressure wound closure device |
| WO2013121725A1 (fr) * | 2012-02-14 | 2013-08-22 | テルモ株式会社 | Dispositif de thérapie et ensemble de thérapie |
| JP6382185B2 (ja) | 2012-05-22 | 2018-08-29 | スミス アンド ネフュー ピーエルシーＳｍｉｔｈ ＆ Ｎｅｐｈｅｗ Ｐｕｂｌｉｃ Ｌｉｍｉｔｅｄ Ｃｏｍｐａｎｙ | 創傷治療のための装置および方法 |
| CN104619359B (zh) | 2012-05-22 | 2018-07-31 | 史密夫及内修公开有限公司 | 伤口愈合装置 |
| MX2014014325A (es) | 2012-05-24 | 2015-08-06 | Smith & Nephew Inc | Dispositivos y metodos para tratar y cerrar heridas con presion negativa. |
| MX369689B (es) | 2012-07-16 | 2019-11-19 | Smith & Nephew Inc | Dispositivo de cierre de herida de presión negativa. |
| WO2014059351A1 (fr) | 2012-10-11 | 2014-04-17 | Tva Medical, Inc. | Dispositifs et procédés pour la formation de fistules |
| JP6407954B2 (ja) | 2013-03-13 | 2018-10-17 | スミス アンド ネフュー インコーポレイテッド | 陰圧創傷閉鎖デバイスおよびシステムならびに陰圧による創傷治療での使用方法 |
| WO2014140578A1 (fr) | 2013-03-14 | 2014-09-18 | Smith & Nephew Plc | Produits compressibles de remplissage de plaies, et systèmes et procédés d'utilisation pour traiter des plaies à l'aide d'une pression négative |
| CA2905591C (fr) | 2013-03-14 | 2023-02-28 | Tva Medical, Inc. | Dispositif de formulation de fistule, et procedes associes |
| CA2918157A1 (fr) | 2013-07-16 | 2015-01-22 | Smith & Nephew Plc | Appareil pour le traitement des plaies |
| AU2014340232B2 (en) | 2013-10-21 | 2019-07-11 | Smith & Nephew Inc. | Negative pressure wound closure device |
| CA2937397A1 (fr) | 2014-01-21 | 2015-07-30 | Smith & Nephew Plc | Appareils de traitement de plaies |
| MX2016009477A (es) | 2014-01-21 | 2016-10-13 | Smith & Nephew | Vendaje plegable para el tratamiento de heridas con presion negativa. |
| US10695534B2 (en) | 2014-03-14 | 2020-06-30 | Tva Medical, Inc. | Fistula formation devices and methods therefor |
| US10646666B2 (en) | 2014-08-27 | 2020-05-12 | Tva Medical, Inc. | Cryolipolysis devices and methods therefor |
| US10603040B1 (en) | 2015-02-09 | 2020-03-31 | Tva Medical, Inc. | Methods for treating hypertension and reducing blood pressure with formation of fistula |
| US11439539B2 (en) | 2015-04-29 | 2022-09-13 | University Of Massachusetts | Negative pressure wound closure device |
| US10575991B2 (en) | 2015-12-15 | 2020-03-03 | University Of Massachusetts | Negative pressure wound closure devices and methods |
| US10814049B2 (en) | 2015-12-15 | 2020-10-27 | University Of Massachusetts | Negative pressure wound closure devices and methods |
| US10874422B2 (en) | 2016-01-15 | 2020-12-29 | Tva Medical, Inc. | Systems and methods for increasing blood flow |
| CN108883251B (zh) | 2016-01-15 | 2021-12-07 | Tva医疗公司 | 用于推进金属丝的装置和方法 |
| WO2017124062A1 (fr) | 2016-01-15 | 2017-07-20 | Tva Medical, Inc. | Dispositifs et procédés de formation d'une fistule |
| MX2018008571A (es) | 2016-01-15 | 2018-11-09 | Tva Medical Inc | Sistemas y metodos para adhesion de vasos. |
| WO2018041805A1 (fr) | 2016-08-30 | 2018-03-08 | Smith & Nephew Plc | Systèmes pour appliquer une thérapie à pression réduite |
| WO2018057095A1 (fr) | 2016-09-25 | 2018-03-29 | Tva Medical, Inc. | Dispositif stents vasculaires et méthodes associées |
| US11096832B2 (en) | 2016-09-27 | 2021-08-24 | Smith & Nephew Plc | Wound closure devices with dissolvable portions |
| JP2019532774A (ja) | 2016-11-02 | 2019-11-14 | スミス アンド ネフュー インコーポレイテッド | 創傷閉鎖器具 |
| US11324876B2 (en) | 2017-06-13 | 2022-05-10 | Smith & Nephew Plc | Collapsible structure and method of use |
| EP3638168B1 (fr) | 2017-06-13 | 2024-10-23 | Smith & Nephew PLC | Dispositif de fermeture de plaie et procédé d'utilisation |
| WO2018229011A1 (fr) | 2017-06-14 | 2018-12-20 | Smith & Nephew Plc | Structure pliable pour fermeture de plaie et méthode d'utilisation |
| US11395873B2 (en) | 2017-06-14 | 2022-07-26 | Smith & Nephew, Inc. | Control of wound closure and fluid removal management in wound therapy |
| US11123476B2 (en) | 2017-06-14 | 2021-09-21 | Smith & Nephew, Inc. | Fluid removal management and control of wound closure in wound therapy |
| CN110740715B (zh) | 2017-06-14 | 2022-04-12 | 史密夫及内修公开有限公司 | 用于伤口闭合的可塌缩片材及使用方法 |
| WO2019020544A1 (fr) | 2017-07-27 | 2019-01-31 | Smith & Nephew Plc | Dispositif de fermeture de plaie personnalisable et son procédé d'utilisation |
| US11590030B2 (en) | 2017-08-07 | 2023-02-28 | Smith & Nephew Plc | Wound closure device with protective layer and method of use |
| WO2019042790A1 (fr) | 2017-08-29 | 2019-03-07 | Smith & Nephew Plc | Systèmes et procédés pour surveiller la fermeture d'une plaie |
| CN110101486B (zh) * | 2018-02-01 | 2024-02-27 | 上海微创心通医疗科技有限公司 | 心脏瓣膜假体及其输送器 |
| US11559384B2 (en) | 2018-06-05 | 2023-01-24 | Boston Scientific Scimed, Inc. | Stent with selectively curved region |
| WO2020096862A1 (fr) * | 2018-11-08 | 2020-05-14 | Edwards Lifesciences Corporation | Traitement percutané d'une insuffisance cardiaque avec fraction d'éjection réduite |
| WO2020124038A1 (fr) | 2018-12-13 | 2020-06-18 | University Of Massachusetts | Dispositifs et méthodes de fermeture de plaie par pression négative |
| KR102432918B1 (ko) * | 2019-03-25 | 2022-08-17 | 연세대학교 산학협력단 | 전기전도 차단을 위한 섬유화 유도 약물 용출 스텐트 |
Citations (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4580568A (en) * | 1984-10-01 | 1986-04-08 | Cook, Incorporated | Percutaneous endovascular stent and method for insertion thereof |
| US5176135A (en) * | 1989-09-06 | 1993-01-05 | Ventritex, Inc. | Implantable defibrillation electrode system |
| US5551426A (en) * | 1993-07-14 | 1996-09-03 | Hummel; John D. | Intracardiac ablation and mapping catheter |
| US5618310A (en) * | 1994-01-21 | 1997-04-08 | Progressive Surgical Products, Inc. | Tissue, expansion and approximation device |
| US5649906A (en) * | 1991-07-17 | 1997-07-22 | Gory; Pierre | Method for implanting a removable medical apparatus in a human body |
| US5837007A (en) * | 1995-12-19 | 1998-11-17 | Pacesetter, Inc. | Intracardiac lead having a compliant fixation device |
| US5910144A (en) * | 1998-01-09 | 1999-06-08 | Endovascular Technologies, Inc. | Prosthesis gripping system and method |
| US6012457A (en) * | 1997-07-08 | 2000-01-11 | The Regents Of The University Of California | Device and method for forming a circumferential conduction block in a pulmonary vein |
| US6267776B1 (en) * | 1999-05-03 | 2001-07-31 | O'connell Paul T. | Vena cava filter and method for treating pulmonary embolism |
| US6443949B2 (en) * | 1997-03-13 | 2002-09-03 | Biocardia, Inc. | Method of drug delivery to interstitial regions of the myocardium |
| US6500186B2 (en) * | 2001-04-17 | 2002-12-31 | Scimed Life Systems, Inc. | In-stent ablative tool |
| US6572652B2 (en) * | 2000-08-29 | 2003-06-03 | Venpro Corporation | Method and devices for decreasing elevated pulmonary venous pressure |
| US6702844B1 (en) * | 1988-03-09 | 2004-03-09 | Endovascular Technologies, Inc. | Artificial graft and implantation method |
Family Cites Families (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5545208A (en) * | 1990-02-28 | 1996-08-13 | Medtronic, Inc. | Intralumenal drug eluting prosthesis |
| US5622698A (en) * | 1990-06-08 | 1997-04-22 | Miami University | Method and composition for increasing the supercooling point in invertebrates |
| US5312456A (en) * | 1991-01-31 | 1994-05-17 | Carnegie Mellon University | Micromechanical barb and method for making the same |
| US5500013A (en) * | 1991-10-04 | 1996-03-19 | Scimed Life Systems, Inc. | Biodegradable drug delivery vascular stent |
| US5234448A (en) * | 1992-02-28 | 1993-08-10 | Shadyside Hospital | Method and apparatus for connecting and closing severed blood vessels |
| US5360440A (en) * | 1992-03-09 | 1994-11-01 | Boston Scientific Corporation | In situ apparatus for generating an electrical current in a biological environment |
| DE69315704T3 (de) | 1992-10-01 | 2002-08-01 | Cardiac Pacemakers, Inc. | Stentartige struktur für entflimmerungselektroden |
| SE9203732D0 (sv) | 1992-12-11 | 1992-12-11 | Siemens Elema Ab | Elektrodsystem foer defibrillator |
| US6010531A (en) * | 1993-02-22 | 2000-01-04 | Heartport, Inc. | Less-invasive devices and methods for cardiac valve surgery |
| US5464650A (en) * | 1993-04-26 | 1995-11-07 | Medtronic, Inc. | Intravascular stent and method |
| US5735892A (en) * | 1993-08-18 | 1998-04-07 | W. L. Gore & Associates, Inc. | Intraluminal stent graft |
| WO1995016407A1 (fr) * | 1993-12-13 | 1995-06-22 | Brigham And Women's Hospital | Dispositif de support de valvule aortique |
| US5423851A (en) * | 1994-03-06 | 1995-06-13 | Samuels; Shaun L. W. | Method and apparatus for affixing an endoluminal device to the walls of tubular structures within the body |
| US5509924A (en) * | 1994-04-12 | 1996-04-23 | Ventritex, Inc. | Epicardial stimulation electrode with energy directing capability |
| US5507779A (en) * | 1994-04-12 | 1996-04-16 | Ventritex, Inc. | Cardiac insulation for defibrillation |
| US5397355A (en) * | 1994-07-19 | 1995-03-14 | Stentco, Inc. | Intraluminal stent |
| US5891108A (en) * | 1994-09-12 | 1999-04-06 | Cordis Corporation | Drug delivery stent |
| US5545183A (en) * | 1994-12-07 | 1996-08-13 | Ventritex, Inc. | Method and apparatus for delivering defibrillation therapy through a sensing electrode |
| US5551427A (en) * | 1995-02-13 | 1996-09-03 | Altman; Peter A. | Implantable device for the effective elimination of cardiac arrhythmogenic sites |
| US6579314B1 (en) * | 1995-03-10 | 2003-06-17 | C.R. Bard, Inc. | Covered stent with encapsulated ends |
| US5674272A (en) * | 1995-06-05 | 1997-10-07 | Ventritex, Inc. | Crush resistant implantable lead |
| US5713863A (en) * | 1996-01-11 | 1998-02-03 | Interventional Technologies Inc. | Catheter with fluid medication injectors |
| DE69526857T2 (de) * | 1995-11-27 | 2003-01-02 | Schneider (Europe) Gmbh, Buelach | Stent zur Anwendung in einem körperlichen Durchgang |
| US5662698A (en) | 1995-12-06 | 1997-09-02 | Ventritex, Inc. | Nonshunting endocardial defibrillation lead |
| US5824030A (en) * | 1995-12-21 | 1998-10-20 | Pacesetter, Inc. | Lead with inter-electrode spacing adjustment |
| US5617878A (en) * | 1996-05-31 | 1997-04-08 | Taheri; Syde A. | Stent and method for treatment of aortic occlusive disease |
| EP0928169A4 (fr) * | 1996-06-25 | 2001-03-28 | Medtronic Inc | Famille de protheses intraluminales possedant des caracteristiques uniformes et procede de fabrication anode |
| JPH1015250A (ja) * | 1996-06-28 | 1998-01-20 | Sega Enterp Ltd | ゲーム装置 |
| HU223957B1 (hu) * | 1996-11-01 | 2005-03-29 | Eurogene Limited | A VEGF fehérje vagy egy ezt kódoló nukleinsav terápiás alkalmazása és implantátum, különösen érbelhártya hiperplázia esetében |
| US5833651A (en) * | 1996-11-08 | 1998-11-10 | Medtronic, Inc. | Therapeutic intraluminal stents |
| US5749890A (en) * | 1996-12-03 | 1998-05-12 | Shaknovich; Alexander | Method and system for stent placement in ostial lesions |
| US5871437A (en) * | 1996-12-10 | 1999-02-16 | Inflow Dynamics, Inc. | Radioactive stent for treating blood vessels to prevent restenosis |
| US6039757A (en) * | 1997-03-12 | 2000-03-21 | Cardiosynopsis, Inc. | In situ formed fenestrated stent |
| US6086582A (en) * | 1997-03-13 | 2000-07-11 | Altman; Peter A. | Cardiac drug delivery system |
| US6425915B1 (en) * | 1997-03-18 | 2002-07-30 | Endotex Interventional Systems, Inc. | Helical mesh endoprosthesis and methods of use |
| US5954761A (en) * | 1997-03-25 | 1999-09-21 | Intermedics Inc. | Implantable endocardial lead assembly having a stent |
| US6096071A (en) * | 1998-03-26 | 2000-08-01 | Yadav; Jay S. | Ostial stent |
| US5843169A (en) * | 1997-04-08 | 1998-12-01 | Taheri; Syde A. | Apparatus and method for stapling graft material to a blood vessel wall while preserving the patency of orifices |
| US5938660A (en) * | 1997-06-27 | 1999-08-17 | Daig Corporation | Process and device for the treatment of atrial arrhythmia |
| US6164283A (en) * | 1997-07-08 | 2000-12-26 | The Regents Of The University Of California | Device and method for forming a circumferential conduction block in a pulmonary vein |
| US6224626B1 (en) * | 1998-02-17 | 2001-05-01 | Md3, Inc. | Ultra-thin expandable stent |
| US6296630B1 (en) * | 1998-04-08 | 2001-10-02 | Biocardia, Inc. | Device and method to slow or stop the heart temporarily |
| US20010044619A1 (en) * | 1998-04-08 | 2001-11-22 | Peter A. Altman | Cardiac drug delivery system and method for use |
| NL1009028C2 (nl) * | 1998-04-28 | 1999-10-29 | Adri Marinus Blomme | Hechtmiddelen voor het verbinden van een buisvormige vaatprothese met een bloedvat in het lichaam alsmede aftakkingsmiddelen, een vaatprothese, een inrichting voor het in het lichaam inbrengen en aanhechten van een vaatprothese en een vaatprothesesysteem. |
| US6206914B1 (en) * | 1998-04-30 | 2001-03-27 | Medtronic, Inc. | Implantable system with drug-eluting cells for on-demand local drug delivery |
| US6179858B1 (en) * | 1998-05-12 | 2001-01-30 | Massachusetts Institute Of Technology | Stent expansion and apposition sensing |
| US6296603B1 (en) * | 1998-05-26 | 2001-10-02 | Isostent, Inc. | Radioactive intraluminal endovascular prosthesis and method for the treatment of aneurysms |
| US6153252A (en) * | 1998-06-30 | 2000-11-28 | Ethicon, Inc. | Process for coating stents |
| US6102887A (en) * | 1998-08-11 | 2000-08-15 | Biocardia, Inc. | Catheter drug delivery system and method for use |
| US6363938B2 (en) * | 1998-12-22 | 2002-04-02 | Angiotrax, Inc. | Methods and apparatus for perfusing tissue and/or stimulating revascularization and tissue growth |
| ES2191480T3 (es) * | 1998-12-31 | 2003-09-01 | Angiotech Pharm Inc | Protesis endovasculares con revestimientos bioactivos. |
| US6210392B1 (en) * | 1999-01-15 | 2001-04-03 | Interventional Technologies, Inc. | Method for treating a wall of a blood vessel |
| IT1307765B1 (it) * | 1999-02-05 | 2001-11-19 | Pietro Quaretti | Endoprotesi tubolare, in particolare per l'uso nei dotti ureterali ebiliari, nonche' nell'esofago. |
| US6161029A (en) * | 1999-03-08 | 2000-12-12 | Medtronic, Inc. | Apparatus and method for fixing electrodes in a blood vessel |
| DE19912635A1 (de) * | 1999-03-20 | 2000-09-21 | Biotronik Mess & Therapieg | Dilatierbare Herzelektrodenanordnung zur Implantation insbesondere im Koronarsinus des Herzens |
| US6245101B1 (en) * | 1999-05-03 | 2001-06-12 | William J. Drasler | Intravascular hinge stent |
| WO2001019270A1 (fr) | 1999-09-15 | 2001-03-22 | The General Hospital Corporation Doing Business As Massachusetts General Hospital | Systeme de catheter d'ablation cardiaque spirale |
| CA2402502A1 (fr) | 1999-10-13 | 2001-04-19 | Biocardia, Inc. | Tuteur intravasculaire de veine pulmonaire et son procede d'utilisation |
| EP1106202A3 (fr) * | 1999-11-30 | 2004-03-31 | BIOTRONIK Mess- und Therapiegeräte GmbH & Co Ingenieurbüro Berlin | Electrode de stimulation, cardioversion et/ou défibrillation intravasculaire |
| US6517573B1 (en) * | 2000-04-11 | 2003-02-11 | Endovascular Technologies, Inc. | Hook for attaching to a corporeal lumen and method of manufacturing |
| US6821295B1 (en) | 2000-06-26 | 2004-11-23 | Thoratec Corporation | Flared coronary artery bypass grafts |
| EP1318766A2 (fr) | 2000-09-21 | 2003-06-18 | Atritech, Inc. | Appareil permettant d'implanter des dispositifs dans des appendices auriculaires |
| US6254632B1 (en) * | 2000-09-28 | 2001-07-03 | Advanced Cardiovascular Systems, Inc. | Implantable medical device having protruding surface structures for drug delivery and cover attachment |
| US20020077691A1 (en) * | 2000-12-18 | 2002-06-20 | Advanced Cardiovascular Systems, Inc. | Ostial stent and method for deploying same |
| EP1365709A2 (fr) | 2001-03-09 | 2003-12-03 | Georgia Tech Research Corporation | Dispositif intravasculaire et procede pour etirer axialement des vaisseaux sanguins |
| US7493162B2 (en) * | 2001-06-15 | 2009-02-17 | Cardiac Pacemakers, Inc. | Pulmonary vein stent for treating atrial fibrillation |
-
2002
- 2002-07-08 WO PCT/US2002/021774 patent/WO2003003948A1/fr not_active Ceased
- 2002-07-08 EP EP02763249A patent/EP1406559A1/fr not_active Ceased
- 2002-07-08 JP JP2003509964A patent/JP2004533890A/ja active Pending
- 2002-07-08 EP EP12185964.9A patent/EP2572674A3/fr not_active Withdrawn
- 2002-07-08 US US10/192,402 patent/US20030055491A1/en not_active Abandoned
- 2002-07-08 AU AU2002327219A patent/AU2002327219B2/en not_active Ceased
- 2002-07-08 CA CA002453210A patent/CA2453210A1/fr not_active Abandoned
-
2006
- 2006-10-20 US US11/551,670 patent/US8579955B2/en not_active Expired - Fee Related
-
2009
- 2009-02-13 JP JP2009032063A patent/JP2009142667A/ja active Pending
-
2013
- 2013-10-28 US US14/065,220 patent/US20140052169A1/en not_active Abandoned
-
2015
- 2015-12-04 US US14/960,266 patent/US20160082234A1/en not_active Abandoned
Patent Citations (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4580568A (en) * | 1984-10-01 | 1986-04-08 | Cook, Incorporated | Percutaneous endovascular stent and method for insertion thereof |
| US6702844B1 (en) * | 1988-03-09 | 2004-03-09 | Endovascular Technologies, Inc. | Artificial graft and implantation method |
| US5176135A (en) * | 1989-09-06 | 1993-01-05 | Ventritex, Inc. | Implantable defibrillation electrode system |
| US5649906A (en) * | 1991-07-17 | 1997-07-22 | Gory; Pierre | Method for implanting a removable medical apparatus in a human body |
| US5551426A (en) * | 1993-07-14 | 1996-09-03 | Hummel; John D. | Intracardiac ablation and mapping catheter |
| US5618310A (en) * | 1994-01-21 | 1997-04-08 | Progressive Surgical Products, Inc. | Tissue, expansion and approximation device |
| US5837007A (en) * | 1995-12-19 | 1998-11-17 | Pacesetter, Inc. | Intracardiac lead having a compliant fixation device |
| US6443949B2 (en) * | 1997-03-13 | 2002-09-03 | Biocardia, Inc. | Method of drug delivery to interstitial regions of the myocardium |
| US6012457A (en) * | 1997-07-08 | 2000-01-11 | The Regents Of The University Of California | Device and method for forming a circumferential conduction block in a pulmonary vein |
| US5910144A (en) * | 1998-01-09 | 1999-06-08 | Endovascular Technologies, Inc. | Prosthesis gripping system and method |
| US6267776B1 (en) * | 1999-05-03 | 2001-07-31 | O'connell Paul T. | Vena cava filter and method for treating pulmonary embolism |
| US6572652B2 (en) * | 2000-08-29 | 2003-06-03 | Venpro Corporation | Method and devices for decreasing elevated pulmonary venous pressure |
| US6500186B2 (en) * | 2001-04-17 | 2002-12-31 | Scimed Life Systems, Inc. | In-stent ablative tool |
Cited By (86)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130317593A1 (en) * | 2000-03-27 | 2013-11-28 | Neovasc Medical Ltd. | Varying diameter vascular implant and balloon |
| US7192438B2 (en) | 2002-11-08 | 2007-03-20 | Margolis James R | Device and method for electrical isolation of the pulmonary veins |
| US20040167598A1 (en) * | 2002-11-08 | 2004-08-26 | Margolis James R. | Device and method for electrical isolation of the pulmonary veins |
| US8409268B2 (en) | 2003-03-03 | 2013-04-02 | Syntach Ag | Electrical conduction block implant device |
| US20100211155A1 (en) * | 2003-03-03 | 2010-08-19 | William Swanson | Electrical Conduction Block Implant Device |
| US8840658B2 (en) * | 2003-03-03 | 2014-09-23 | Syntach Ag | Electrical conduction block implant device |
| US20090171445A1 (en) * | 2003-03-03 | 2009-07-02 | William Swanson | Electrical Conduction Block Implant Device |
| US20130211317A1 (en) * | 2003-11-17 | 2013-08-15 | Syntach Ag | Device, A Kit And A Method For Treatment Of Disorders In The Heart Rhythm Regulation System |
| US9295484B2 (en) * | 2003-11-17 | 2016-03-29 | Syntach Ag | Device, a kit and a method for treatment of disorders in the heart rhythm regulation system |
| US8257376B2 (en) * | 2003-11-17 | 2012-09-04 | Syntach Ag | Device, a kit and a method for treatment of disorders in the heart rhythm regulation system |
| US20050131503A1 (en) * | 2003-11-17 | 2005-06-16 | Synergio Ag | Device, a kit and a method for treatment of disorders in the heart rhythm regulation system |
| US20090264880A1 (en) * | 2003-11-17 | 2009-10-22 | Jan Otto Solem | Device, A Kit And A Method For Treatment Of Disorders In The Heart Rhythm Regulation System |
| US20090264983A1 (en) * | 2003-11-17 | 2009-10-22 | Jan Otto Solem | Device, A Kit And A Method For Treatment Of Disorders In The Heart Rhythm Regulation System |
| US9398967B2 (en) * | 2004-03-02 | 2016-07-26 | Syntach Ag | Electrical conduction block implant device |
| US20060178725A1 (en) * | 2004-03-02 | 2006-08-10 | Sinus Rhythm Technologies, Inc. | Electrical conduction block implant device |
| US20050234540A1 (en) * | 2004-03-12 | 2005-10-20 | Nmt Medical, Inc. | Dilatation systems and methods for left atrial appendage |
| US20080200945A1 (en) * | 2004-03-19 | 2008-08-21 | Aga Medical Corporation | Device for occluding vascular defects |
| US9445799B2 (en) | 2004-03-19 | 2016-09-20 | St. Jude Medical, Cardiology Division, Inc. | Multi-layer braided structures for occluding vascular defects |
| US10624619B2 (en) | 2004-03-19 | 2020-04-21 | St. Jude Medical, Cardiology Division, Inc. | Multi-layer braided structures for occluding vascular defects and for occluding fluid flow through portions of the vasculature of the body |
| US8777974B2 (en) | 2004-03-19 | 2014-07-15 | Aga Medical Corporation | Multi-layer braided structures for occluding vascular defects |
| US9039724B2 (en) | 2004-03-19 | 2015-05-26 | Aga Medical Corporation | Device for occluding vascular defects |
| US9445798B2 (en) | 2004-03-19 | 2016-09-20 | St. Jude Medical, Cardiology Division, Inc. | Multi-layer braided structures for occluding vascular defects |
| US20090062841A1 (en) * | 2004-03-19 | 2009-03-05 | Aga Medical Corporation | Device for occluding vascular defects |
| US9877710B2 (en) | 2004-03-19 | 2018-01-30 | St. Jude Medical, Cardiology Division, Inc. | Multi-layer braided structures for occluding vascular defects and for occluding fluid flow through portions of the vasculature of the body |
| US20070265656A1 (en) * | 2004-03-19 | 2007-11-15 | Aga Medical Corporation | Multi-layer braided structures for occluding vascular defects |
| US20060241690A1 (en) * | 2004-03-19 | 2006-10-26 | Aga Medical Corporation | Multi-layer braided structures for occluding vascular defects and for occluding fluid flow through portions of the vasculature of the body |
| US8398670B2 (en) | 2004-03-19 | 2013-03-19 | Aga Medical Corporation | Multi-layer braided structures for occluding vascular defects and for occluding fluid flow through portions of the vasculature of the body |
| US8313505B2 (en) | 2004-03-19 | 2012-11-20 | Aga Medical Corporation | Device for occluding vascular defects |
| EP1809195A4 (fr) * | 2004-10-08 | 2010-01-20 | Syntach Ag | Generation de cicatrice en deux etapes pour le traitement de la fibrillation auriculaire |
| JP2008515566A (ja) * | 2004-10-08 | 2008-05-15 | シンタッハ アクチェンゲゼルシャフト | 心房細動治療のための２段階瘢痕生成 |
| US20090171444A1 (en) * | 2004-10-08 | 2009-07-02 | Richard Cornelius | Two-Stage Scar Generation for Treating Atrial Fibrillation |
| US20060116666A1 (en) * | 2004-10-08 | 2006-06-01 | Sinus Rhythm Technologies, Inc. | Two-stage scar generation for treating atrial fibrillation |
| WO2006042246A2 (fr) | 2004-10-08 | 2006-04-20 | Syntach Ag | Generation de cicatrice en deux etapes pour le traitement de la fibrillation auriculaire |
| US7387604B2 (en) * | 2004-11-03 | 2008-06-17 | Cook Incorporated | Methods for treating valve-associated regions of vascular vessels |
| US20060116548A1 (en) * | 2004-11-03 | 2006-06-01 | Cook, Incorporated | Methods for treating valve-associated regions of vascular vessels |
| US20080312676A1 (en) * | 2005-05-17 | 2008-12-18 | Jan Otto Solem | Device And Kit For Treatment Of Disorders In The Heart Rhythm Regulation System |
| US8696696B2 (en) | 2005-05-17 | 2014-04-15 | Syntach Ag | Device and kit for treatment of disorders in the heart rhythm regulation system |
| US20110015722A1 (en) * | 2005-09-09 | 2011-01-20 | Edwards Lifesciences Corporation | Device and method for reshaping mitral valve annulus |
| US8652201B2 (en) | 2006-04-26 | 2014-02-18 | The Cleveland Clinic Foundation | Apparatus and method for treating cardiovascular diseases |
| US20070255389A1 (en) * | 2006-04-26 | 2007-11-01 | The Cleveland Clinic Foundation | Apparatus and method for treating cardiovascular diseases |
| US9114035B2 (en) | 2006-04-26 | 2015-08-25 | The Cleveland Clinic Foundation | Apparatus and method for treating cardiovascular diseases |
| US20100016877A1 (en) * | 2006-05-17 | 2010-01-21 | Syntach Ag | Controllable Device, A Kit And A Method For Treatment Of Disorders In The Heart Rhythm Regulation System |
| US20100268323A1 (en) * | 2006-06-08 | 2010-10-21 | Daniel Sullivan | Inflammation Accelerating Prosthesis |
| US20100305603A1 (en) * | 2007-10-17 | 2010-12-02 | Stevan Nielsen | Shape-Changing Medical Device, Kit, Method Of Production, And Method Of Use |
| US9974670B2 (en) | 2007-12-12 | 2018-05-22 | Intact Vascular, Inc. | Method of treating atherosclerotic occlusive disease |
| US20140194967A1 (en) * | 2007-12-12 | 2014-07-10 | Intact Vascular, Inc. | Device and method for tacking plaque to blood vessel wall |
| US10799374B2 (en) | 2007-12-12 | 2020-10-13 | Intact Vascular, Inc. | Device and method for tacking plaque to blood vessel wall |
| US10117762B2 (en) | 2007-12-12 | 2018-11-06 | Intact Vascular, Inc. | Endoluminal device and method |
| US10299945B2 (en) | 2007-12-12 | 2019-05-28 | Intact Vascular, Inc. | Method of treating atherosclerotic occlusive disease |
| US10278839B2 (en) | 2007-12-12 | 2019-05-07 | Intact Vascular, Inc. | Endovascular impant |
| US10166127B2 (en) | 2007-12-12 | 2019-01-01 | Intact Vascular, Inc. | Endoluminal device and method |
| US10660771B2 (en) | 2007-12-12 | 2020-05-26 | Intact Vacsular, Inc. | Deployment device for placement of multiple intraluminal surgical staples |
| US10188533B2 (en) | 2007-12-12 | 2019-01-29 | Intact Vascular, Inc. | Minimal surface area contact device for holding plaque to blood vessel wall |
| US10022250B2 (en) | 2007-12-12 | 2018-07-17 | Intact Vascular, Inc. | Deployment device for placement of multiple intraluminal surgical staples |
| US10835395B2 (en) * | 2007-12-12 | 2020-11-17 | Intact Vascular, Inc. | Method of treating atherosclerotic occlusive disease |
| US20090210048A1 (en) * | 2008-02-18 | 2009-08-20 | Aga Medical Corporation | Stent/stent graft for reinforcement of vascular abnormalities and associated method |
| US8747453B2 (en) | 2008-02-18 | 2014-06-10 | Aga Medical Corporation | Stent/stent graft for reinforcement of vascular abnormalities and associated method |
| US20200268279A1 (en) * | 2008-07-25 | 2020-08-27 | ResMed Pty Ltd | Method and apparatus for detecting and treating heart failure |
| WO2010033725A3 (fr) * | 2008-09-20 | 2010-06-10 | Steven Craig Anderson | Appareil et procédé pour l’adhérence d’un tissu |
| US9592040B2 (en) * | 2008-09-20 | 2017-03-14 | Micokoll Inc. | Apparatus and method for tissue adhesion |
| US10888443B2 (en) * | 2009-06-11 | 2021-01-12 | Intact Vascular, Inc. | Device for holding plaque to blood vessel wall |
| US20190192321A1 (en) * | 2009-06-11 | 2019-06-27 | Intact Vascular, Inc. | Device for holding plaque to blood vessel wall |
| US10779971B2 (en) | 2009-06-11 | 2020-09-22 | Intact Vascular, Inc. | Endovascular implant |
| US10137013B2 (en) | 2010-05-29 | 2018-11-27 | Intact Vascular, Inc. | Endoluminal device and method |
| US10779968B2 (en) | 2010-05-29 | 2020-09-22 | Intact Vascular, Inc. | Endoluminal device and method |
| WO2012016886A3 (fr) * | 2010-07-26 | 2012-05-10 | Hans Reiner Figulla | Implant médical pour la stabilisation endovasculaire de parois de vaisseaux et procédé de fabrication d'un tel implant |
| US20150051708A1 (en) * | 2011-03-17 | 2015-02-19 | Microkoll Inc. | Apparatus and method for tissue adhesion |
| US9138233B2 (en) * | 2011-03-17 | 2015-09-22 | Micokoll Inc. | Apparatus and method for tissue adhesion |
| US9526572B2 (en) | 2011-04-26 | 2016-12-27 | Aperiam Medical, Inc. | Method and device for treatment of hypertension and other maladies |
| US10271973B2 (en) | 2011-06-03 | 2019-04-30 | Intact Vascular, Inc. | Endovascular implant |
| US10390977B2 (en) | 2011-06-03 | 2019-08-27 | Intact Vascular, Inc. | Endovascular implant |
| US10285831B2 (en) | 2011-06-03 | 2019-05-14 | Intact Vascular, Inc. | Endovascular implant |
| US10779969B2 (en) | 2011-06-03 | 2020-09-22 | Intact Vascular, Inc. | Endovascular implant and deployment devices |
| US8934988B2 (en) * | 2012-03-16 | 2015-01-13 | St. Jude Medical Ab | Ablation stent with meander structure |
| US20130245621A1 (en) * | 2012-03-16 | 2013-09-19 | St. Jude Medical Ab | Ablation stent and method of using an ablation stent |
| US11304836B2 (en) | 2015-01-29 | 2022-04-19 | Intact Vascular, Inc. | Delivery device and method of delivery |
| US10898356B2 (en) | 2015-01-29 | 2021-01-26 | Intact Vascular, Inc. | Delivery device and method of delivery |
| US10245167B2 (en) | 2015-01-29 | 2019-04-02 | Intact Vascular, Inc. | Delivery device and method of delivery |
| WO2016145391A1 (fr) * | 2015-03-11 | 2016-09-15 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Système de greffe cardiovasculaire expansible |
| US10426593B2 (en) | 2015-03-11 | 2019-10-01 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Expansible cardiovascular graft system |
| US10172729B2 (en) | 2015-10-12 | 2019-01-08 | Reflow Medical, Inc. | Stents having protruding drug-delivery features and associated systems and methods |
| US10258487B2 (en) | 2015-10-12 | 2019-04-16 | Reflow Medical, Inc. | Stents having protruding drug-delivery features and associated systems and methods |
| US11253379B2 (en) | 2015-10-12 | 2022-02-22 | Reflow Medical, Inc. | Stents having protruding drug-delivery features and associated systems and methods |
| US10993824B2 (en) | 2016-01-01 | 2021-05-04 | Intact Vascular, Inc. | Delivery device and method of delivery |
| US11660218B2 (en) | 2017-07-26 | 2023-05-30 | Intact Vascular, Inc. | Delivery device and method of delivery |
| WO2025188999A1 (fr) * | 2024-03-07 | 2025-09-12 | Edwards Lifesciences Corporation | Gestion de pression élevée de remplissage côté gauche |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2003003948A1 (fr) | 2003-01-16 |
| AU2002327219B2 (en) | 2009-04-23 |
| JP2004533890A (ja) | 2004-11-11 |
| EP2572674A3 (fr) | 2013-08-07 |
| US20140052169A1 (en) | 2014-02-20 |
| JP2009142667A (ja) | 2009-07-02 |
| EP1406559A1 (fr) | 2004-04-14 |
| CA2453210A1 (fr) | 2003-01-16 |
| US8579955B2 (en) | 2013-11-12 |
| EP2572674A2 (fr) | 2013-03-27 |
| US20070049866A1 (en) | 2007-03-01 |
| US20160082234A1 (en) | 2016-03-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8579955B2 (en) | Anti-arrhythmia devices and methods of use | |
| AU2002327219A1 (en) | Anti-arrhythmia devices and methods of use | |
| US6692520B1 (en) | Systems and methods for imbedded intramuscular implants | |
| US12465485B2 (en) | Interatrial shunts having biodegradable material, and methods of making and using same | |
| RU2372052C2 (ru) | Устройство, комплект и способ для лечения нарушений в системе регуляции ритма сердца | |
| US7209783B2 (en) | Ablation stent for treating atrial fibrillation | |
| US7493162B2 (en) | Pulmonary vein stent for treating atrial fibrillation | |
| US8409268B2 (en) | Electrical conduction block implant device | |
| US7155295B2 (en) | Cardiac harness for treating congestive heart failure and for defibrillating and/or pacing/sensing | |
| US6620170B1 (en) | Devices and methods for treating ischemia by creating a fibrin plug | |
| US20140171853A1 (en) | Device And Kit For Treatment Of Disorders In The Heart Rhythm Regulation System | |
| WO2020217194A1 (fr) | Shunts interauriculaires contenant un matériau biodégradable et leurs procédés de fabrication et d'utilisation | |
| US20180154123A1 (en) | Implants and systems for electrically isolating one or more pulminary veins | |
| US6342051B1 (en) | Treatment of anoxic tissue with angiogenesis-inducing implants |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AS | Assignment |
Owner name: TRICARDIA, LLC, MINNESOTA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SCHWARTZ, ROBERT S.;VAN TASSEL, ROBERT A.;HOLMES, DAVID R. JR.;REEL/FRAME:013350/0279;SIGNING DATES FROM 20020916 TO 20020920 |
|
| AS | Assignment |
Owner name: SINUS RHYTHM TECHNOLOGIES, INC., MINNESOTA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:TRICARDIA, LLC;REEL/FRAME:014434/0727 Effective date: 20040116 |
|
| AS | Assignment |
Owner name: RICK CORNELIUS AS TRUSTEE FOR SRTI LIQUIDATING TRU Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:SINUS RHYTHM TECHNOLOGIES, INC.;REEL/FRAME:018688/0433 Effective date: 20061227 |
|
| STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |
|
| AS | Assignment |
Owner name: SYNTACH AG, SWITZERLAND Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:RICK CORNELIUS AS TRUSTEE OF SRTI LIQUIDATING TRUST;REEL/FRAME:018883/0530 Effective date: 20070213 |